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A B S T R A C T
Background
One-third of subfertile couples have no identifiable cause for their inability to conceive. In vitro fertilisation (IVF) is a widely accepted
treatment for this condition; however, this treatment is invasive and expensive and is associated with risks.
Objectives
To evaluate the effectiveness and safety of IVF compared with expectant management, unstimulated intrauterine insemination (IUI)
or intrauterine insemination along with ovarian stimulation with gonadotropins (IUI + gonadotropins) or clomiphene (IUI + CC) or
letrozole (IUI + letrozole) in improving pregnancy outcomes.
Search methods
This review has drawn on the search strategy developed by the Cochrane Menstrual Disorders and Subfertility Group. We searched
the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched May 2015), the Cochrane Central Register of
Controlled Trials (CENTRAL; 2015, first quarter), MEDLINE (1946 to May 2015), EMBASE (1985 to May 2015), the Cumulative
Index to Nursing and Allied Health Literature (CINAHL) (May 2015) and reference lists of articles. We searched the following trial
registries: clinicaltrials.gov (http://www.clinicaltrials.gov) and the World Health Organization International Trials Registry Platform
search portal (http://www.who.int/trialsearch/Default.aspx). We searched the Web of Science (http://wokinfo.com/) as another source
of trials and conference abstracts, OpenGrey (http://www.opengrey.eu/) for unpublished literature fromEurope and the Latin American
Caribbean Health Sciences Literature (LILACS) database (http://regional.bvsalud.org/php/index.php?lang=en). Moreover, we hand-
searched relevant conference proceedings and contacted study authors to ask about additional publications.
Two review authors independently assessed trial eligibility, extracted data and assessed risk of bias. The primary review outcome was
cumulative live birth rate. Multiple pregnancy and other adverse effects were secondary outcomes. We combined data to calculate
pooled risk ratios (RRs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity by using the I2 statistic. We assessed
the overall quality of evidence for the main comparisons using Grades of Recommendation, Assessment, Development and Evaluation
(GRADE) methods.
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Selection criteria
We included randomised controlled trials (RCTs) in which the effectiveness of IVF in couples with unexplained subfertility was
compared with that of other treatments, including expectant management, unstimulated IUI and stimulated IUI using gonadotropins
or clomiphene or letrozole.
Live birth rate (LBR) per woman was the primary outcome.
Data collection and analysis
Two review authors independently assessed the eligibility and quality of trials and evaluated the quality of the evidence by using GRADE
criteria.
Main results
IVF versus expectant management (two RCTs):
Live birth rate per woman was higher with IVF than with expectant management (odds ratio (OR) 22.00, 95% confidence interval
(CI) 2.56 to 189.37, one RCT, 51 women, very low quality evidence). Multiple pregnancy rates (MPRs), ovarian hyperstimulation
syndrome (OHSS) and miscarriage were not reported.
IVF versus unstimulated IUI (two RCTs):
Live birth rate was higher with IVF than with unstimulated IUI (OR 2.47, 95% CI 1.19 to 5.12, two RCTs, 156 women, I2 = 60%,
low quality evidence). There was no evidence of a difference between the groups in multiple pregnancy rates (OR 1.03, 95% CI 0.04
to 27.29, one RCT, 43 women, very low quality evidence)
IVF versus IUI + ovarian stimulation with gonadotropins (three RCTs) or clomiphene (one RCT) or letrozole (no RCTs):
Data from these trials could not be pooled because of high statistical heterogeneity (I2 = 93.3%). Heterogeneity was eliminated when
studies were stratified by pretreatment status.
In trials comparing IVF versus IUI + gonadotropins among treatment-naive women, there was no conclusive evidence of a difference
between the groups in live birth rates (OR 1.27, 95% CI 0.94 to 1.73, four RCTs, 745 women, I2 = 8.0%, moderate-quality evidence).
In women pretreated with IUI + clomiphene, a higher live birth rate was reported among those who underwent IVF than those given
IUI + gonadotropins (OR 3.90, 95% CI 2.32 to 6.57, one RCT, 280 women, moderate-quality evidence).There was no conclusive
evidence of a difference in live birth rates between IVF and IUI + CC in treatment-naive women (OR 2.51, 95% CI 0.96 to 6.55, one
RCT, 103 women, low quality evidence).
In treatment-naive women, there was no evidence of a difference in rates of multiple pregnancy between women who underwent IVF
and those who received IUI + gonadotropins (OR 0.79, 95% CI 0.45 to 1.39, four RCTs, 745 women, I2 = 0%, moderate quality
evidence). There was no evidence of a difference in MPRs between women who underwent IVF compared with those given IUI + CC
(OR 1.02, 95% CI 0.20 to 5.31, one RCT, 103 women, low-quality evidence).
There was no evidence of a difference in ovarian hyperstimulation syndrome rate between treatment-naive women who underwent
IVF and those given IUI + gonadotropins (OR 1.23, 95% CI 0.36 to 4.14, two RCTs, 221 women, low quality evidence). There was
no evidence of a difference in OHSS rates between groups receiving IVF versus those receiving IUI + CC (OR 1.02, 95% CI 0.20 to
5.31, one RCT, 103 women, low-quality evidence).
In treatment naive women, there was no evidence of a difference in miscarriage rates between IVF and IUI + CC (OR 1.16, 95%
CI 0.44 to 3.02, one RCT, 103 women, low-quality evidence), nor between women treated with IVF versus those receiving IUI+
gonadotropins (OR 1.16, 95% CI 0.44 to 3.02, one RCT, 103 women).
No studies compared IVF with IUI + letrozole.
The quality of the evidence ranged from very low to moderate. The main limitation was serious imprecision resulting from small study
numbers and low event rates.
Authors’ conclusions
IVFmay be associatedwith higher live birth rates than expectantmanagement, but there is insufficient evidence to drawfirmconclusions.
IVF may also be associated with higher live birth rates than unstimulated IUI. In women pretreated with clomiphene + IUI, IVF
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appears to be associated with higher birth rates than IUI + gonadotropins. However in women who are treatment-naive there is no
conclusive evidence of a difference in live birth rates between IVF and IUI + gonadotropins or between IVF and IUI + clomiphene.
Adverse events associated with these interventions could not be adequately assessed owing to lack of evidence.
P L A I N L A N G U A G E S U M M A R Y
In vitro fertilisation (IVF) compared to other options for unexplained subfertility
Review question: Cochrane review authors investigated whether IVF leads to more live births than other management options in
women with unexplained subfertility.
Background: IVF is frequently used for couples with unexplained subfertility, as it may bypass a variety of undiagnosed biological
problems. However, it is expensive and invasive and can lead to complications. Other management options for unexplained subfertility
include trying naturally for a pregnancy, introducing washed sperm within the womb (insemination) and performing insemination
after use of drugs (’fertility drugs’) to stimulate the ovaries.
Study characteristics: The eight randomised parallel-group trials included 1622 women. Some were multi-arm trials with several
comparisons. Two compared IVF with expectant management, two compared IVF with insemination alone (IUI) and five compared
IVF with insemination plus stimulation of the ovaries. Evidence is current to May 2015.
Key results: IVF may be associated with higher live birth rates than expectant management, but there is insufficient evidence to draw
firm conclusions. IVF may also be associated with higher live birth rates than unstimulated IUI. In women pretreated with clomiphene
+ IUI, IVF appears to be associated with higher birth rates than IUI plus gonadotropins. However in women who are treatment-naive
there is no conclusive evidence of a difference in live birth rates between IVF and IUI + gonadotrophins or between IVF and IUI +
clomiphene. Adverse events associated with these interventions could not be adequately assessed owing to lack of evidence.
Quality of the evidence: Quality of the evidence ranged from very low to moderate. The main limitation was serious imprecision
resulting from small study numbers and low event rates.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IVF compared with expectant management for unexplained subfertility
Population: women with unexplained subfertility
Settings: fertility clinic
Intervention: IVF
Comparison: expectant management
Outcomes Plain language sum-
mary
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Expectant management IVF
Live birth rate per
woman
IVF vs expectant manage-
ment
There is inconclusive evi-
dence to suggest that IVF
may result in more births
than expectant manage-
ment
37 per 1000 458 per 1000
(90 to 879)
OR 22
(2.56 to 189.37)
51
(1 study)
⊕©©©
Very lowa
Pregnancy rate per
woman
IVF vs expectant manage-
ment
There is inconclusive evi-
dence to suggest that IVF
may result in more clini-
cal pregnancies than ex-
pectant management
127 per 1000 320 per 1000
(135 to 588)
OR 3.24
(1.07 to 9.8)
86
(2 studies)
⊕©©©
Very lowa
Multiple pregnancy rate Not reported in the included studies
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; IVF: In vitro fertilisation; OR: Odds ratio.
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aThe GRADE quality rating was downgraded by 3 levels due to very serious imprecision, questionable applicability and (for the analysis
of clinical pregnancy) serious inconsistency. Very few events were reported in the included studies (12 births and 18 pregnancies
altogether). There was also substantial statistical heterogeneity (I2=80%) in the analysis of clinical pregnancies (with differing
directions of effect) and applicability was unclear due to the long duration of unexplained infertility and use of co-interventions.
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B A C K G R O U N D
Description of the condition
Infertility is said to be unexplained when standard investigations
fail to reveal any obvious barrier to conception such as absent
ovulation, poor semen quality or tubal pathology. The prevalence
of unexplained infertility among couples attending a fertility clinic
has been shown to be 21% among women younger than 35 years
of age and 26% in women older than 35 years (Maheshwari 2008).
In the absence of a known cause for infertility, treatment options
have included expectant management, unstimulated intrauter-
ine insemination (IUI), stimulated IUI with clomiphene or go-
nadotropins and in vitro fertilisation (IVF). IVF is expected to
overcome any subtle biological deficiencies that could affect con-
ception. However, it is invasive and is associated with risks such
as multiple pregnancy and ovarian hyperstimulation syndrome
(OHSS).
NICE 2013 recommends offering IVF to women with unex-
plained infertility who have not conceived after two years of regu-
lar unprotected sexual intercourse. In the UK, estimated live birth
rates (LBRs) per IVF treatment for all indications of IVF vary
between 32.2% in women younger than 35 years and 13.4% in
women between 40 and 42 years of age (HFEA 2012), and the av-
erage LBR per cycle started is 25% (HFEA 2012). The Victorian
Assisted Reproductive Treatment Authority in Australia (VARTA
2013) and the FIVNAT2012 report from France have noted preg-
nancy rates per commenced cycle of 18.3% and 20.8%, respec-
tively. The American Society for Reproductive Medicine/Society
for Assisted Reproductive Technology Registry (ASRM/SART)
reported that 40.7% of cycles resulted in a live birth in women
younger than 35 years (SART/ASRM 2014).
The chance that pregnancy will lead to live birth is influenced by
the prognostic profile of a couple such as female age, duration of
infertility and previous pregnancy (Collins 1995). Invasive treat-
ments such as IVF are thought to be more effective than expectant
management for couples with limited chances of natural concep-
tion, but less so in couples with good prospects of natural concep-
tion.
Description of the intervention
In vitro fertilisation involves using standard protocols for con-
trolled ovarian stimulation, oocyte retrieval under ultrasound
guidance, insemination, embryo culture and transcervical replace-
ment of embryos at cleavage or blastocyst stage. In comparison
with cleavage stage transfer, blastocyst transfer results show a sig-
nificant increase in LBRper fresh IVF cycle (Glujovsky 2012). IVF
is invasive and is associated with several potential complications.
The multiple pregnancy rate (MPR) (including twins and triplets)
associated with IVF is approximately 18.8% (HFEA 2012). In
2006, the risk of having twins following IVF and intracytoplasmic
sperm injection (ICSI) was 19.9%, and that of having triplets was
0.9%(Mouzon 2010).MPRs after single embryo transfer anddou-
ble embryo transfer have been reported to be 1.5% and 32.4%, re-
spectively (SART/ASRM 2014). The incidence of OHSS in stim-
ulated IVF cycles in Europe was reported to be 0.8% in 2006
(Mouzon 2010). OHSS can present with different grades of sever-
ity (mild,moderate, severe). The intravascular depletion associated
with OHSS can lead to dehydration, hypovolaemia, electrolyte
disturbances and thrombosis due to haemoconcentration.
Other treatments that have been used in unexplained subfertility
include IUI (with or without superovulation (SO)) and expectant
management (spontaneous pregnancy).
IUI, with or without concomitant use of clomiphene citrate (CC)
or gonadotrophins, or letrozole, is a widely used treatment for un-
explained infertility (NICE 2013). By bypassing the cervical bar-
rier and increasing the number of motile spermatozoa that reach
the uterus and tubes, thereby bringing the sperm in close proxim-
ity to one or more eggs, IUI can improve fertilisation and could
increase LBRs.
Unstimulated IUI
In a spontaneous cycle, single or dual IUI is normally performed
20 to 30 hours after an endogenous luteinising hormone (LH)
surge is detected in the serum or urine. Women are asked to mon-
itor urinary or serum LH levels daily from day 10 to day 12 of the
treatment cycle. Normally, a maximum of 0.5 mL suspension of
processed spermatozoa is introduced into the uterine cavity with
a suitable catheter. Semen is prepared by using a standard pure
sperm preparation (a procedure used to prepare semen to isolate
a population of sperm with a higher percentage of motile forms
and with a more uniform morphology than those found in un-
treated ejaculates). The procedure involves processing fresh and
liquefied ejaculates over a pure sperm gradient of 80/40, followed
by centrifugation. Couples are advised to abstain from intercourse
from the day of LH monitoring until the day of insemination.
Additional luteal support is not required.
IUI + ovarian stimulation with gonadotropins
For ovarian stimulation + IUI cycles, CC (antiestrogen) or go-
nadotropins are used. The aim is to achieve ovulation from a max-
imum of two mature follicles. The enhanced fertility induced by
ovarian stimulation can be attributed to the increased number of
fertilisable oocytes, improved sperm selection and assisted migra-
tion. The advantage of this approach is that some of the risks as-
sociated with IVF are avoided, particularly those related to oocyte
retrieval. However, significant risks of OHSS and multiple preg-
nancy remain if gonadotropins are used concomitantly.
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IUI + gonadotropins
When gonadotropins are used concomitantly with IUI, a baseline
ultrasound scan is carried out between days 1 and 3 of the treat-
ment cycle. A daily or alternate-day dose of 75 IUof gonadotropins
is started from day 3, and follicular tracking is carried out from
around day 5 of stimulation. Subtle variations in clinical protocol
would be found with different clinics. When one or two follicles
reach 17 mm in maximum diameter, urinary or serum LH levels
are estimated to rule out endogenous surge, a human chorionic
gonadotropin (hCG) trigger is given intramuscularly and the IUI
is planned 36 to 40 hours later. In the case of excessive response
of more than two mature follicles, the cycle is cancelled to avoid
risk of high-order multiple pregnancies. Luteal support generally
is not required.
IUI + CC
Clomiphene therapy involves oral administration of CC tablets at
a dose of 50 mg to 250 mg daily for five days in the early follicular
phase (usually from day 2 to day 6) of the cycle. Follicular tracking
is carried out from day 10 to day 12 of the treatment cycle. Once a
follicle reaches 17 to 18 mm inmaximum diameter, urinary LH or
serum LH levels are estimated to rule out endogenous LH surge,
an HCG trigger is given intramuscularly and IUI is carried out 36
to 40 hours later.
IUI + letrozole
Letrozole (aromatase inhibitor) therapy involves oral administra-
tion of letrozole tablets at a dose of 2.5 mg to 5 mg daily for five
days in the early follicular phase (usually from day 2 to day 6)
of the cycle. Follicular tracking is carried out from day 8 to day
10 of the treatment cycle. Once a follicle reaches 17 to 18 mm
in maximum diameter, an hCG trigger may or may not be given
intramuscularly, and IUI is carried out 24 to 40 hours later.
Expectant management
In the absence of an identified cause, couples with unexplained
infertility have a relatively high chance of spontaneous pregnancy
(Lenton 1977; Collins 1995; Snick 1997; Steures 2006; Steures
2008). A cumulative LBR of 33% at 36 months was estimated
from a Canadian multi-centre cohort study (Collins 1995). Fol-
lowing this report, Snick 1997 presented data from a primary care
study in the Netherlands and suggested a cumulative LBR of 60%
at 36 months.
In an RCT (Steures 2006) that compared expectant management
with IUI plus SO in couples with unexplained subfertility, of the
253 couples enrolled, 127 were assigned IUI with controlled ovar-
ian hyperstimulation, and 126 expectant management. In the in-
tervention group, 42 (33%)women conceived and 29 (23%) preg-
nancies were ongoing. In the expectant management group, 40
(32%) women conceived and 34 (27%) pregnancies were ongoing
(risk ratio (RR) 0.85, 95% confidence interval (CI) 0.63 to 1.1).
One twinpregnancy occurred in each study group, andonewoman
in the intervention group conceived triplets. This study concluded
that a large beneficial effect of IUI with controlled ovarian hyper-
stimulation can be excluded in couples with unexplained subfertil-
ity and an intermediate prognosis. Expectant management for six
months was therefore justified in these couples and is an efficient
way to prevent multiple pregnancies.
In a Scottish multi-centre trial, 580 couples with unexplained in-
fertility that included mild endometriosis and mild male factor in-
fertility were randomly assigned to three arms: expectant manage-
ment, CC and IUI (Bhattacharya 2008). Live birth rates of 17%
and 23% were obtained after expectant management and IUI, re-
spectively, and no evidence suggested differences (odds ratio (OR)
1.46, 95% CI 0.88 to 2.43). Clinical pregnancy rates were similar
in the two groups (expectant group 17% vs 23% in the IUI group)
(OR 1.41, 95% CI 0.73 to 2.74). This study suggested that 17
women would need to undergo IUI for one extra live birth to be
achieved.
A Cochrane review (Hughes 2010) pooled data from two trials
comparing CC with IUI and expectant management and showed
no clinical benefit with CC and IUI (OR 2.40, 95% CI 0.70 to
8.19).
How the intervention might work
IVF can potentially circumvent many of the putative causes of
unexplained infertility by bypassing several in vivo steps that may
be responsible for lack of conception. These include ovarian dys-
function, cervical factors, problems with sperm and egg transport
and sperm-egg interaction.
Why it is important to do this review
IVF is invasive and expensive and is associatedwith risks. This is an
update of a Cochrane review first published in 2002 and updated
in 2005 and 2011. This review evaluates current evidence compar-
ing IVF with other, less invasive treatments, including expectant
management for unexplained infertility. Comparisons within the
review should assist couples and clinicians in choosing the best
treatment for unexplained infertility. Current limitations in the
literature and future areas of research are highlighted in the review.
O B J E C T I V E S
To evaluate the effectiveness and safety of IVF compared with
expectant management, unstimulated intrauterine insemination
(IUI) or intrauterine insemination along with ovarian stimulation
with gonadotropins (IUI + gonadotropins) or clomiphene (IUI +
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CC) or letrozole (IUI + letrozole) in improving pregnancy out-
comes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs).
Cross-over trials were included if first-phase results could be ex-
tracted.
Types of participants
• Couples with unexplained infertility.
• Couples with minimal endometriosis (American Fertility
Society (AFS) criteria grade I) with subfertility or mild male
factor subfertility who have been trying to conceive for one year
or longer.
Types of interventions
The study had to include one ormore comparisons of effectiveness.
• In vitro fertilisation (IVF) versus expectant management.
• IVF versus intrauterine insemination (IUI) alone.
• IVF versus IUI plus ovarian stimulation with
gonadotropins or clomiphene or letrozole.
Types of outcome measures
Primary outcomes
1. Live birth rate (LBR) per woman. Live birth is defined as the
delivery of one or more living infants. LBR per woman is defined
as the number of live births for each randomly assigned woman
over a particular period of time.
Secondary outcomes
2. Pregnancy rate per woman. Demonstration of foetal heart ac-
tivity on an ultrasound scan defines an ongoing clinical pregnancy.
Presence of a gestational sac on ultrasound scan or confirmation of
products of conception by pathological examination in the event
of spontaneous abortion or ectopic pregnancy defines a clinical
pregnancy. Pregnancy rate per woman is defined as the number of
pregnancies for each randomly assigned woman over a particular
period of time.
3. Multiple pregnancy rate (MPR) per woman. Demonstration of
more than one sac with a foetal pole on ultrasound scan defines
multiple pregnancy.Multiple pregnancy rate per woman is defined
as the number of multiple pregnancies for each randomly assigned
woman over a particular period of time.
4. Incidence of ovarian hyperstimulation syndrome (OHSS) per
woman.
5. Miscarriage rate per woman, defined as the number of miscar-
riages for each randomly assigned woman over a particular period
of time.
Search methods for identification of studies
The original search was performed in July 2001. Updated searches
were completed in August 2004, May 2007, March 2010, July
2011 and May 2015. Updated searches were independently per-
formed by ZP, AG and Marion Showell (Trials Search Co-or-
dinator, Cochrane Menstrual Disorders and Subfertility Group
(MDSG)).
We used the MDSG search string (Appendix 1).
Electronic searches
We searched the following electronic databases.
• Evidence-based medicine (EBM) Reviews (Appendix 1).
• MEDLINE (Appendix 2).
• EMBASE (Appendix 3).
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 4).
• PsycINFO (Appendix 5).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (Appendix 6).
Searching other resources
We searched the citation lists of relevant publications, review ar-
ticles and included studies. We handsearched relevant conference
proceedings and sent personal communications to experts and au-
thors in the field.
Data collection and analysis
See Appendix 7.
Selection of studies
One review author (ZP) scanned the titles and abstracts of articles
retrieved by the search and removed those that were clearly irrel-
evant. We retrieved the full texts of all potentially eligible stud-
ies. Two review authors (ZP, AG) independently examined full-
text articles for compliance with the inclusion criteria and selected
studies eligible for inclusion in the review. ZP corresponded with
study investigators, when required, to clarify study eligibility. Re-
view authors resolved disagreements regarding study eligibility by
consensus or by discussion with a third review author (SB).
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Data extraction and management
Two review authors (ZP, SB) selected trials for inclusion in the
review, employing the search strategy described previously. We
detailed excluded studies in a table of excluded trials. We analysed
included trials for the quality criteria and methodological details
outlined below.Wepresented this information in a table describing
the included studies, which provides a context for discussing the
reliability of results.
Two review authors (ZP, AG) independently assessed trial qual-
ity and extracted data, using forms designed in accordance with
Cochrane guidelines.We resolved discrepancies by discussion with
a senior review author (SB). We sought additional information
on trial methodology or actual original data from the principal
authors of trials that appeared to meet eligibility criteria but were
unclear in aspects of methodology, or when data were provided in
a form that was unsuitable for meta-analysis. We sent reminders
to study authors if we received no reply four weeks after making
the initial request.
Assessment of risk of bias in included studies
See Figure 1 and Figure 2.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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We assessed all included studies for risk of bias by using the
Cochrane ’Risk of bias’ assessment tool (Figure 1) to assess se-
quence generation; allocation concealment; blinding of partici-
pants, providers and outcome assessors; completeness of outcome
data; selective outcome reporting; and other potential sources of
bias. Two review authors (ZP, AG) assessed these six domains and
resolved disagreements by consensus or by discussion with a third
review author (SB). We have presented conclusions in the ’Risk of
bias’ tables (see the Characteristics of included studies table).
When identified studies failed to report the primary outcome of
live birth but reported interimoutcomes such as pregnancy rate, we
informally assessed whether those reporting the primary outcome
provided typical values for interim outcomes.
Measures of treatment effect
We expressed results for each study as odds ratios with 95% con-
fidence intervals.
We used dichotomous data for primary and some secondary out-
come measures for this review. We expressed results for each study
as odds ratios with 95% confidence intervals and combined them
for meta-analysis with RevMan software using a Mantel-Haenszel
fixed-effect model.
When outcome data were reported as a percentage of the total
number of participants, we included this information in the anal-
yses by multiplying the percentage number by the total number
of participants (n) in that group and dividing by 100.
We considered pregnancy outcomes as positive consequences of
treatment; therefore, we considered a higher proportion of women
achieving pregnancy or higher numbers of oocytes to be benefi-
cial. MPRs and OHSS were negative consequences, so that we
considered higher numbers to be detrimental. We considered this
when designing and viewing summary graphs.
Unit of analysis issues
Weperformed the primary analysis perwoman randomly assigned.
When possible, we extracted per-woman data from trials that re-
ported data per cycle.
We counted multiple live births (e.g. twins, triplets) as one live
birth event.
Dealing with missing data
We analysed data on an intention-to-treat basis as far as possible
and attempted to obtain missing data from the original investiga-
tors. When we could not access missing data after attempting to
contact the primary authors, we used data that were available.
Assessment of heterogeneity
Review authors considered whether clinical and methodologi-
cal characteristics of included studies were sufficiently similar for
meta-analysis to provide a meaningful summary. Even when trials
included in a comparison group were statistically homogeneous,
we noted potentially large differences in clinical features (clini-
cal heterogeneity). We took these differences into account when
analysing and interpreting pooled results. Clinical heterogeneity
in subfertility (such as variation in entry criteria and subtle dif-
ferences in treatments used, which are important from a clinical
perspective) cannot be avoided because most centres use their own
protocols, which can vary in different aspects. When trials met
the inclusion criteria and investigators had provided the same in-
tervention, we considered it appropriate to pool their results. We
assessed statistical heterogeneity by inspecting scatter in the data
points and overlap in the confidence intervals and, more formally,
by checking results of the Chi2 test and measuring the I2 statistic.
We considered an I2 value greater than 50% to indicate substantial
heterogeneity (Higgins 2011). If we detected substantial hetero-
geneity, we explored possible explanations by performing sensitiv-
ity analyses.
Assessment of reporting biases
In view of the difficulty involved in detecting and correcting for
publication bias and other reporting biases, we aimed to minimise
their potential impact by ensuring a comprehensive search for
eligible studies and by staying alert for duplication of data.
Data synthesis
We combined data from primary studies by using the fixed-effect
model in the following comparisons.
• IVF versus expectant management.
• IVF versus unstimulated IUI.
• IVF versus IUI + ovarian stimulation with gonadotropins
or IUI + CC or IUI + letrozole.
We graphically displayed an increase in the odds of a particular
outcome, which may be beneficial (e.g. live birth) or detrimental
(e.g. multiple pregnancy), in meta-analyses to the right of the
centre line, and we showed a decrease in the odds of an outcome
to the left of the centre line.
We combined results for each study for meta-analysis with
RevMan software using the Peto-modified Mantel-Haenszel
method.
We considered the outcome of clinical pregnancy a positive con-
sequence of treatment; therefore, we regarded a higher proportion
of women with pregnancy as a benefit. Outcomes such as OHSS
and multiple pregnancy were a negative consequence; therefore,
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we considered higher numbers to be detrimental. The reader must
consider this when viewing summary graphs.
Subgroup analysis and investigation of heterogeneity
Wedetermined possible contributions of differences in trial design
to identified heterogeneity.
Sensitivity analysis
We performed sensitivity analysis to determine whether conclu-
sions of the review would have differed if eligibility were restricted
to studies without high risk of bias by:
• using a funnel plot, if possible, to explore the possibility of
small-study effects (a tendency for estimates of the intervention
effect to be more beneficial in smaller studies); and
• testing the effects of using a random-effects model and of
providing RRs rather than ORs.
Overall quality of the body of evidence: Summary of
findings table
We prepared a ’Summary of findings’ table to evaluate the over-
all quality of the body of evidence for main review outcomes
(live birth, clinical pregnancy, miscarriage), using GRADE criteria
(study limitations (i.e. risk of bias), consistency of effect, impreci-
sion, indirectness and publication bias). We justified, documented
and incorporated into reporting of results judgements about evi-
dence quality (high, moderate or low) for each outcome.
R E S U L T S
Description of studies
Results of the search
We identified 411 articles in our search. When the title or the
abstract identified a study as possibly eligible, or if we had any
doubt about exclusion of a study, we obtained the full article for
further evaluation. We excluded 405/411 articles, as they did not
meet the basic inclusion criteria of the review as identified by their
titles and abstracts, or because theywere duplicated in the different
databases searched (Figure 3).
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Figure 3. Study flow diagram.
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Of the remaining six articles (Custers 2012; Elzeiny 2014;
Goldman 2014; van Rumste 2014; Bensdorp 2015; Nandi 2015),
three are new trials eligible for inclusion in this update (Bensdorp
2015; Elzeiny 2014; Goldman 2014) and one (van Rumste 2014)
is a follow up of Custers et al 2011 and van Rumste 2009 that
were included in the previous update of this review as two separate
studies. Nandi 2015 is a study registered in theWorld Health Or-
ganization (WHO) trial registry and we classified it as an ongoing
study. We excluded one study (Custers 2012: see Excluded studies
table). Consequently, we included a total of eight trials in this
updated review, comprising three new studies (Bensdorp 2015;
Elzeiny 2014; Goldman 2014) and five from the previous ver-
sion of the review (Soliman 1993; Goverde 2000; Hughes 2004;
Reindollar 2010; van Rumste 2014).
We sought additional information from study authors when rel-
evant, and we received a response from two authors (Goldman
2014; van Rumste 2014). We have provided a flowchart for the
review search results in Figure 3. As relatively few studies were
available for analysis, we could not use a funnel plot to explore
the possibility of small-study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies)
in comparisons 1 and 2. We did not perform subgroup analyses
for mild endometriosis as planned because most studies did not
identify such subgroups. Sensitivity analysis to determine whether
conclusions of the review would have differed if eligibility were
restricted to studies without high risk of bias was not required, as
we found no significant differences in risk of bias among included
trials.
Included studies
We included eight trials in this review (Soliman 1993; Goverde
2000; Hughes 2004; Reindollar 2010; Elzeiny 2014; Goldman
2014; van Rumste 2014; Bensdorp 2015).
Trial design characteristics
Design
The eight included studies were randomised parallel-group trials.
Interventions
Two studies compared in vitro fertilisation (IVF) with expectant
management (Soliman 1993; Hughes 2004). The duration of ex-
pectant management was three months in one study (Hughes
2004) and six months in the other (Soliman 1993).
Two studies compared IVF with intrauterine insemination (IUI)
alone (Goverde 2000; Elzeiny 2014). One of these compared the
effectiveness of IVF (six cycles) versus unstimulated IUI (six cycles)
(Goverde 2000). The second compared the effectiveness of one
cycle of IVF versus one cycle of unstimulated IUI (Elzeiny 2014).
Five studies compared IVF with IUI plus ovarian stimulation
with gonadotropins (Goverde 2000; Reindollar 2010; Goldman
2014; van Rumste 2014; Bensdorp 2015). One study analysed
IUI + CC and IUI + FSH (follicle-stimulating hormone) sepa-
rately (Goldman 2014). Both arms of Reindollar 2010 received
IUI plus clomiphene citrate (IUI + CC) before going on to IUI
+ gonadotropins or IVF. No studies compared IVF with IUI +
letrozole.
Multi-centre trials
Five trials were multi-centre studies (Hughes 2004; Reindollar
2010; Goldman 2014; van Rumste 2014; Bensdorp 2015).
Statistical analysis
Two studies used the Chi2 test for analysis of discrete data on
the characteristics of participants and cycles and the Student’s t-
test to analyse continuous data (Soliman 1993; Goverde 2000).
One study used Fisher’s exact test and calculated confidence inter-
vals using the Mantel-Haenszel method (Hughes 2004). Another
study used Fisher’s exact test and exact binomial 95% confidence
intervals (Reindollar 2010). One study expressed results as risk
ratios and 95% confidence intervals (Bensdorp 2015). One study
(Elzeiny 2014) used one-tailed P Fisher’s exact tests to compare
categorical variables between study groups and represented con-
tinuous data as means ± standard deviations and analysed them
using Student’s t-test. Another study (Goldman 2014) stated that
exact binomial 97.5% confidence intervals were calculated. One
study used rate ratios for ongoing pregnancy with corresponding
95% confidence intervals. A formal test of differences in preg-
nancy rates was performed using Chi2 test statistics (van Rumste
2014).
Financial support or sponsorship
Four trials stated sponsorship. One study (Soliman 1993) was
funded by ProvincialHealth Insurance,Ontario, Canada. Another
was supported by a grant from the National Institutes of Health,
Rockville, Maryland, USA (Reindollar 2010). One study (Elzeiny
2014) was financially supported by Serono (Geneva, Switzerland)
and Melbourne IVF (Melbourne, Australia), another by a grant
from ZonMW, the Dutch organisation for Health Research and
Development and a grant from Zorgverzekeraars Nederland, the
Dutch association of health care insurers.(Bensdorp 2015).
We did not perform subgroup analyses for mild endometriosis
because most studies did not identify such subgroups. As data on
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effectiveness of treatments compared were insufficient, we did not
carry out sensitivity analyses.
Baseline characteristics of participants
All studies included couples with unexplained infertility in whom
baseline infertility investigations were normal, but inclusion cri-
teria differed among the studies.
One study included women between 21 and 39 years of age
(Reindollar 2010), and another included women between 18 and
42 years of age (Elzeiny 2014). Another study included women be-
tween18 and38years of age (Bensdorp 2015).One study included
women between 38 and 42 years of age (Goldman 2014), and
other studies did not mention an age limit for inclusion (Goverde
2000; van Rumste 2014). In one trial, women were included if the
duration of infertility was three years (Goverde2000). Aminimum
duration of infertility of two years was an inclusion criterion in an-
other trial (Hughes 2004). Infertility for one year was the inclusion
criterion in three studies (Soliman 1993; Reindollar 2010; Elzeiny
2014). One study included couples who had a poor prospect of
pregnancy, defined as a chance of natural conception within 12
months below30% (Custers 2011a).One study that included only
women between 38 and 42 years of age had an eligibility criterion
of six months of attempted conception (Goldman 2014). Four
studies included couples withmildmale factor infertility (Goverde
2000; Reindollar 2010; van Rumste 2014; Bensdorp 2015), and
another included couples with endometriosis American Fertility
Society (AFS) stage I (Goverde 2000).
With regard to the studies of expectantmanagement, one (Soliman
1993) included 245 women <40 years of age with varied diagnoses
for subfertility and a mean duration of subfertility of 65 months.
This study included 35 women with unexplained infertility, who
are included in this review. The other 210 women are not included
in analysis. The other study of expectant management (Hughes
2004) included women between 18 and 39 years of age with a
mean duration of subfertility of 56 months. Most women in this
study had unexplained or male factor infertility, and all had patent
fallopian tubes. Women in both of these studies had exhausted
other treatment options.
Outcomes studied
Primary outcome
• Live birth rate (LBR) per woman: Six trials reported LBR
per woman or couple as an outcome (Goverde 2000; Hughes
2004; Reindollar 2010; Elzeiny 2014; Goldman 2014; Bensdorp
2015).
Secondary outcomes
• Pregnancy rate per woman: Eight trials reported pregnancy
rate per woman or couple as an endpoint (Soliman 1993;
Goverde 2000; Hughes 2004; Reindollar 2010; Elzeiny 2014;
Goldman 2014; van Rumste 2014; Bensdorp 2015).
• Multiple pregnancy rate (MPR) per woman: Five studies
determined MPR per woman (Goverde 2000; Elzeiny 2014;
Goldman 2014; van Rumste 2014; Bensdorp 2015).
• Ovarian hyperstimulation syndrome (OHSS): Two studies
reported incidence of OHSS as an outcome (Goverde 2000;
Goldman 2014).
See the Characteristics of excluded studies table.
Excluded studies
See Characteristics of excluded studies.
We excluded eight studies from analysis after checking the full
text (Leeton 1987; Crosignani 1991; Jarrell 1993; Raneiri 1995;
Zayed 1997; Karande 1998; Tanbo 1990; Custers 2012). Two
studies did not perform diagnostic stratification before analysis
(Jarrell 1993; Karande 1998). One study was a quasi-randomised
trial (Leeton 1987), another study allocated women by pseudo-
randomisation (Zayed 1997), and one did not include an IVF arm.
(Custers 2012).We excluded from the current update three studies
that had been included in an earlier version of this review: one
(Crosignani 1991) because valid pregnancy and LBR data could
not be extracted, and two because they compared IVFwith gamete
intrafallopian transfer (GIFT) (Tanbo 1990; Raneiri 1995), which
was not a comparison of interest for this update.
Risk of bias in included studies
See Characteristics of included studies (Figure 1) (Figure 2).
Allocation
Random sequence generation
All eight studies were at low risk of bias for sequence generation.
Of the eight included studies, two used computer-generated ran-
domisation (Goverde 2000; Elzeiny 2014). One study used a
computer-generated random numbers table (Soliman 1993). An-
other used an online randomisation programme with biased coin
minimisation stratified for study centre (Bensdorp 2015). One
study based randomisation on a blocked schedule by using num-
bered, sealed, opaque envelopes (Hughes 2004). Another study
performed randomisation using permuted blocks of varying sizes,
stratified by the woman’s age (< 35 vs ≥ 35 years), laparoscopy
within the past year (yes or no) and study site (Boston IVF or
Harvard Vanguard Medical Associates) (Reindollar 2010). One
other study performed randomisation using permuted blocks of
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varying sizes, which were stratified by the woman’s age (38th to
41st vs 42nd to 43rd birthday) (Goldman 2014). Another trial
used central Internet-based randomisation, which was stratified
for centre (van Rumste 2014).
Allocation concealment
Six studies were at low risk of bias in terms of allocation conceal-
ment, and the level of risk was unclear in two. Three studies used
sealed envelopes (Goverde 2000; Hughes 2004; Elzeiny 2014).
Two studies did not state concealment of allocation (Soliman
1993; van Rumste 2014). Allocation concealment was unclear in
one study (Reindollar 2010). One study stated that the alloca-
tion sequence was generated by an independent biostatistician and
was implemented by an epidemiologist (Goldman 2014). Another
study stated that a unique number with allocation code was gen-
erated by a Web-based programme after participant initials and
date of birth were entered. Neither recruiters not the trial project
group could access the randomisation sequence (Bensdorp 2015).
Blinding
Two studies were at low risk of bias because of blinding, and six
were at unclear risk. Blinding of participants and clinicians was
not possible because of the nature of the interventions. However,
one study stated that investigators were blinded to all outcome
determinations (Reindollar 2010), and another study stated that
all clinical investigators were blinded to outcome determinations
(Goldman 2014). Blinding appears unlikely to affect outcomes
measured in the review.
Incomplete outcome data
Seven studies were at low risk of attrition bias, and one was at high
risk.
Six trials performed intention-to-treat analysis (Soliman 1993;
Goverde 2000; Hughes 2004; Reindollar 2010; Goldman 2014;
Bensdorp 2015). Numbers of withdrawals and dropouts were re-
ported in six trials (Soliman 1993; Goverde 2000; Hughes 2004;
Reindollar 2010; van Rumste 2014; Bensdorp 2015). One study
mentioned the number of women excluded after randomisation
but did not perform an intention-to-treat analysis (Elzeiny 2014).
For this update, we requested from study authors data that were in-
complete or that were not clearly reported in the paper (Reindollar
2010; van Rumste 2014).
Selective reporting
To avoid selective reporting and reporting bias, we performed a
comprehensive search for eligible studies and ensured that no data
were duplicated.
Seven studies were deemed to be at low risk of selective reporting
bias, and the risk associated with one was unclear. No evidence
suggested that the decision to publish or failure to publish any
specific outcomes by authors of included studies was based on
perceived statistical significance.
Other potential sources of bias
Six studies were at low risk of other potential biases, and two were
at high risk. Seven studies included a priori power calculations
in their reports (Soliman 1993; Goverde 2000; Hughes 2004;
Reindollar 2010; Elzeiny 2014; Goldman 2014; Bensdorp 2015).
Effects of interventions
See: Summary of findings for the main comparison
IVF compared with expectant management for unexplained
subfertility; Summary of findings 2 IVF compared with
unstimulated IUI for unexplained subfertility; Summary of
findings 3 IVF compared with IUI + superovulation for
unexplained subfertility
1 IVF versus expectant management
This was tested in two trials (Soliman 1993; Hughes 2004).
Primary outcome
1.1 Live birth rate (LBR)
LBR per woman or couple with a single cycle of IVF was sig-
nificantly higher than with three months of expectant manage-
ment (odds ratio (OR) 22.0, 95% confidence interval (CI) 2.56
to 189.38, 51 women). This was tested in a single trial (Hughes
2004) (Analysis 1.1; Figure 4). The quality of evidencewas deemed
to be very low.
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Figure 4. Forest plot of comparison: 1 IVF versus expectant management, outcome: 1.1 Live birth rate per
woman.
Secondary outcomes
1.2 Clinical pregnancy rate (CPR)
CPR per woman or couple associated with a single cycle of IVF
was significantly higher than with three to six months of expectant
management (OR 3.24, 95% CI 1.07 to 9.80, two RCTs, 86
women, I2 = 80%, 28.9% vs 12.2%) (Analysis 1.2; Figure 5). The
quality of evidence was deemed to be very low. Heterogeneity was
high, as the studies had differing directions of effect.
Figure 5. Forest plot of comparison: 1 IVF versus expectant management, outcome: 1.2 Clinical pregnancy
rate per woman.
These studies did not report the other review outcomes (MPR,
OHSS, miscarriage). 2. IVF versus unstimulated IUI
Two trials compared the effectiveness of IVF versus unstimulated
IUI.
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One trial compared the effectiveness of IVF (six cycles) versus
unstimulated IUI (six cycles) (Goverde 2000). The second trial
compared the effectiveness of one cycle of IVF versus one cycle of
unstimulated IUI (Elzeiny 2014).
Primary outcome
2.1 Live birth rate (LBR)
IVF was associated with a higher live birth rate than IUI (OR
2.47, 95% CI 1.19 to 5.12, two RCTs, 156 women, I2 = 60%)
(Analysis 2.1; Figure 6). The quality of evidence was deemed to
be low.
Figure 6. Forest plot of comparison: 2 IVF versus unstimulated IUI, outcome: 2.1 Live birth rate per woman.
Secondary outcomes
2.2 Clinical pregnancy rate (CPR)
There was no evidence of a difference between IVF and IUI in
CPR (OR 4.83, 95% CI 0.94 to 24.95, one RCT, 44 women, I2
= 80%) (Analysis 2.2;). The quality of evidence was deemed to be
low.
2.3 Multiple pregnancy rate (MPR)
There was no evidence of a difference in MPR between the two
groups (OR 1.03, 95% CI 0.04 to 27.29, one RCT, 44 women, I2
not applicable (Analysis 2.3)). The quality of evidence was deemed
to be very low.
These studies did not report the other review outcomes (OHSS,
miscarriage).
3. IVF versus IUI + ovarian stimulation with
gonadotropins (IUI + gonadotropins) or clomiphene
citrate (IUI + CC)
Five trials compared effectiveness of IVF versus IUI + go-
nadotropins (Goverde 2000; Reindollar 2010; Goldman 2014;
van Rumste 2014; Bensdorp 2015).
• Goverde 2000: This trial compared effectiveness of a
maximum of six cycles of IUI after mild ovarian
hyperstimulation with IVF.
• Reindollar 2010: This trial compared three cycles of IUI +
gonadotropins versus six cycles of IVF in women pretreated with
clomiphene + IUI.
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• Goldman 2014: This trial compared two cycles of
clomiphene + IUI versus one cycle of IVF, and two cycles of
recombinant FSH + IUI versus one cycle of IVF.
• van Rumste 2014: This trial compared three cycles of IUI +
gonadotropins versus one cycle of IVF.
• Bensdorp 2015: This trial compared three cycles of IVF-
SET(plus subsequent cryo cycles) versus six cycles of IUI +
gonadotropins.
Primary outcome
3.1 Live birth rate (LBR)
Five studies reported live birth rates (Goverde 2000; Reindollar
2010; Goldman 2014; van Rumste 2014; Bensdorp 2015). These
studies were not pooled because of high statistical heterogeneity
(I2 = 93.3%). Heterogeneity was eliminated when studies were
stratified by pretreatment status, that is, treatment-naive women
underwent IUI along with gonadotropins (Goverde 2000; van
Rumste 2014;Goldman 2014; Bensdorp 2015), or treatment-
naive women underwent IUI along with CC (Goldman 2014) or
women were pretreated (Reindollar 2010).
IVF versus IUI + gonadotropins
Among treatment-naive women, there was no evidence of a dif-
ference in LBR between IVF and IUI + gonadotropins (OR 1.27,
95% CI 0.94 to 1.73, four RCTs, 745 women, I2 = 26%, mod-
erate-quality evidence), but in pretreated women, a significantly
higher LBR was noted in those who underwent IVF compared
with IUI + gonadotropins (OR 3.90, 95% CI 2.32 to 6.57, one
RCT, 280 women) (Analysis 3.1; Figure 7). Evidence was of mod-
erate quality.
Figure 7. Forest plot of comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or
clomiphene (CC), outcome: 3.1 Live birth rate per woman.
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IVF versus IUI + CC
There was no evidence of a difference in LBR between IVF and
IUI +CC (OR2.51, 95%CI 0.96 to 6.55, one RCT, 103women).
Evidence was of low quality.
Secondary outcomes
3.2 Clinical pregnancy rate (CPR)
Four studies reported CPR per woman (Reindollar 2010;
Goldman 2014; van Rumste 2014; Bensdorp 2015). These stud-
ies were not pooled because statistical heterogeneity was high (I2
= 96.3%). Heterogeneity was eliminated when studies were strat-
ified by pretreatment status, that is, treatment-naive women un-
derwent IUI with gonadotropins (van Rumste 2014;Goldman
2014; Bensdorp 2015), or treatment-naive womenunderwent IUI
with CC (Goldman 2014) or women were pretreated (Reindollar
2010).
IVF versus IUI + gonadotropins
Among treatment-naive women, significant differences between
IVF and IUI+ gonadotropinswere seen inCPR (OR1.45, 95%CI
1.03 to 2.03, three RCTs, 627 women, I2 = 73%) (Analysis 3.2),
but in pretreated women, the pregnancy rate was higher among
those who underwent IVF compared with IUI + gonadotropins
(OR 14.13, 95% CI 7.57 to 26.38, one RCT, 280 women). These
results should be interpretedwith caution because of the wide con-
fidence interval (Analysis 3.2; Figure 8). Evidence was of moderate
quality.
Figure 8. Forest plot of comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or
clomiphene (CC), outcome: 3.2 Clinical pregnancy rate per woman.
IVF versus IUI + CC
For the subgroup of treatment-naive women who received either
IVF or IUI + CC, pregnancy rates were higher in the IVF group
(OR 4.59, 95% CI 1.86 to 11.35, one RCT, 103 women)
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3.3 Multiple pregnancy rate (MPR)
Four trials reported MPR per woman (Goverde 2000; Goldman
2014; van Rumste 2014; Bensdorp 2015) (Analysis 3.3; Figure 9).
Figure 9. Forest plot of comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or
clomiphene (CC), outcome: 3.3 Multiple pregnancy rate per woman.
IVF versus IUI + gonadotropins
Moderate-quality evidence showed no evidence of a difference in
MPR between treatment-naive women who underwent IVF and
those given IUI + gonadotropins (OR 0.79, 95% CI 0.45 to 1.39,
four RCTs, 745 women, I2=0%)
IVF versus IUI + CC
There was no evidence of a difference in MPR between women
who had IVF compared with those given IUI + CC (OR 1.02,
95%CI 0.20 to 5.31, one RCT, 103 women) (Analysis 3.3; Figure
9).
3.4 Incidence of ovarian hyperstimulation syndrome (OHSS)
Two studies determined the incidence of OHSS (Goverde 2000;
Goldman 2014).
IVF versus IUI + gonadotropins
Low-quality evidence showed no evidence of a difference inOHSS
rate between treatment-naive women who underwent IVF and
those given IUI + gonadotropins (OR 1.23, 95% CI 0.36 to 4.14,
two RCTs, 221 women, I2=0%)
IVF versus IUI + CC
Low-quality evidence showed no evidence of a difference inOHSS
rate between the IVF group and the IUI + CC group (OR 1.02,
95% CI 0.20 to 5.31, one RCT, 103 women, I2 = 0%). Evidence
was of low quality (Analysis 3.4).
3.5 Miscarriage rate
One study reportedmiscarriage rate perwoman in treatment-naive
women (Goldman 2014).
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IVF versus IUI+ gonadotropins
There was no evidence of a difference in miscarriage rates between
the IVF group and the IUI+ gonadotropins group (OR 1.16, 95%
CI 0.44 to 3.02, one RCT, 103 women)
IVF versus IUI + CC
There was no evidence of a difference in miscarriage rates between
the IVF group and the IUI+ CC group (OR 1.16, 95% CI 0.44 to
3.02, oneRCT, 103women). Evidencewas of lowquality (Analysis
3.5).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
IVF compared with unstimulated IUI for unexplained subfertility
Population: women with unexplained subfertility
Setting: fertility clinic
Intervention: IVF
Comparison: unstimulated IUI
Outcomes Plain language sum-
mary
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Unstimulated IUI IVF
Live birth rate
IVF vs IUI
Evidence suggests that
IVF may result in more
births than insemina-
tion without using fertility
drugs
160 per 1000 320 per 1000
(185 to 494)
OR 2.47
(1.19 to 5.12)
156
(2 studies)
⊕⊕©©
Lowa
Pregnancy rate
IVF vs IUI
It is unclear whether there
is a difference in the preg-
nancy rate resulting from
IVF compared with in-
semination without using
fertility drugs, due to in-
sufficient evidence
121 per 1000 400 per 1000
(115 to 775)
OR 4.83
(0.94 to 24.95)
43
(1 study)
⊕⊕©©
Very lowb
Multiple pregnancy rate It is unclear whether there
is a difference in themulti-
ple pregnancy rate result-
ing from IVF compared
with insemination without
using fertility drugs, due
to insufficient evidence
30 per 1000 31 per 1000
(1 to 460)
OR 1.03
(0.04 to 27.29)
43
(1 study)
⊕©©©
Very lowc
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*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; IUI: Intrauterine insemination; OR: Odds ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aThe GRADE quality rating was downgraded by 2 levels due to serious imprecision: There were only 44 events. There was also substantial
statistical heterogeneity (I2=60%), though the direction of effect was consistent.
bThe GRADE quality rating was downgraded by 3 levels due to very serious imprecision, with only 8 events. The confidence interval is
compatible with no difference between the groups or with a large benefit in the IVF group.
cThe GRADE quality rating was downgraded by 3 levels due to very serious imprecision: there was only one event in this analysis
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IVF compared with IUI + superovulation for unexplained subfertility
Population: women with unexplained subfertility
Setting: fertility clinic
Intervention: IVF
Comparison: IUI + superovulation
Outcomes Plain language sum-
mary
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
IUI + superovulation IVF
Live birth rate in treat-
ment-naive women
IVF vs IUI + go-
nadotropins
In treatment-naive
women there is no con-
clusive evidence of a dif-
ference in live birth rates
between IVF and insem-
ination using injectable
fertility drugs
273 per 1000 308 per 1000
(264 to 360)
OR 1.27
(0.94 to 1.73)
745
(4 studies)
⊕⊕⊕©
Moderatea
Live birth rate in pre-
treated women
IVF vs IUI + go-
nadotropins
In women pretreated with
oral fertility drugs IVF
leads to more live births
than insemination using
injectable fertility drugs
219 per 1000 523 per 1000
(374 to 731)
OR 3.90
(2.32 to 6.57)
280
(1 study)
⊕⊕⊕©
Moderateb
Live birth rate in treat-
ment-naive women
IVF vs IUI + CC
In treatment-naive
women there is no con-
clusive evidence of a dif-
ference in live birth rates
between IVF and insem-
ination using injectable
fertility drugs
154 per 1000 314 per 1000
(148 to 668)
OR 2.51
(0.96 to 6.55)
103
(1 study)
⊕⊕©©
Lowc
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Multiple pregnancy rate In treat-
ment-naive women there
is no evidence of a dif-
ference in multiple preg-
nancy rates between IVF
and insemination using
injectable fertility drugs
58 per 1000 47 per 1000
(28 to 78)
OR 0.81
(0.47 to 1.39)
848
(4 studies)
⊕⊕⊕©
Moderated
Incidence of OHSS In treat-
ment-naive women there
is no evidence of a differ-
ence in OHSS rates be-
tween IVF and insemina-
tion using injectable fertil-
ity drugs
58 per 1000 66 per 1000
(26 to 158)
OR 1.15
(0.43 to 3.06)
324
(2 studies)
⊕⊕©©
Lowe
*The basis for the assumed risk is the median risk in the control groups. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CC: Clomiphene citrate; CI: Confidence interval; IUI: Intrauterine insemination; IVF: In vitro fertilisation; OHSS: Ovarian hyperstimulation syndrome; OR: Odds ratio ;RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aThe GRADE quality rating was downgraded by 1 level due to serious imprecision: the confidence interval is compatible with no difference
between the interventions or with meaningful benefit from IVF.
bThe GRADE quality rating was downgraded by 1 level due to the relatively small number of events (n=97) in the single included trial.
cThe GRADE quality rating was downgraded by 2 levels due to very serious imprecision: there were only 24 events and the confidence
interval is compatible with no difference between the interventions or with meaningful benefit from IVF
dThe GRADE quality rating was downgraded by 1 level due to serious imprecision: the confidence interval is compatible with no difference
between the interventions or with meaningful benefit in either arm.
eThe GRADE quality rating was downgraded by 2 levels due to serious imprecision, risk of bias in one trial and the small number of
events in the included trials. The confidence interval is compatible with no difference between the interventions or with meaningful benefit
in either arm.
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison, Summary of
findings 2 and Summary of findings 3.
In vitro fertilisation (IVF) results in higher live birth rates (LBRs)
compared with expectant management or unstimulated intrauter-
ine insemination (IUI). LBRs with IVF are also higher compared
with those seen with IUI + gonadotropins in women pretreated
with clomiphene citrate (CC), but no evidence suggests differ-
ences in LBR between IVF and IUI + gonadotropins in treatment-
naive women. Nor does evidence show differences in LBR be-
tween IVF and IUI + CC. IVF results in higher clinical pregnancy
rates (CPR) compared to IUI + gonadotropins in treatment naive
women. Adverse events associated with these interventions have
not been adequately reported; additional research is necessary.
Overall completeness and applicability of
evidence
Evidence for each comparison was limited. The primary outcome
for this review was LBR per woman. Only one study (Bensdorp
2015) followed couples for 12 months after randomisation, dur-
ing which time they underwent a maximum of three IVF cycles
with subsequent transfer of a single fresh and (when appropriate)
frozen embryo, or amaximumof six cycles of IUI + gonadotropins.
Duration of infertility among couples included in the trials var-
ied significantly. No trials compared IVF with IUI + letrozole.
The paucity of trials and possible clinical heterogeneity among
included trials suggest that evidence for the effectiveness of IVF is
inconclusive.
Meta-analysis was possible for three comparisons (IVF vs expec-
tant management, IVF vs unstimulated IUI, IVF vs IUI + go-
nadotropins), but as few outcomes were reported, pooling was
limited because data were insufficient. One of the included tri-
als, which compared IVF with expectant management, dates from
1993 (Soliman 1993). IVF versus CC + IUI was represented by a
single trial. Although risk of bias was not substantial in the trial
included in this comparison, it is difficult to be confident about
this, as all trials share similar weaknesses, as discussed above. Ad-
verse events associated with these interventions have not been ad-
equately reported.
The applicability of studies comparing IVF versus expectant man-
agement is questionable, as they included extensively pretreated
women who had been subfertile for several years (mean 58-65
months) and the durationof expectantmanagementwas only three
to six months.
Small studies of treatment-naive women found no significant
differences in LBR per woman between IVF and IUI + go-
nadotropins.Clinical pregnancy rates were significantly higher
with IVF compared with IUI+ gonadotropins. However, a large
study of women pretreated with CC + IUI reported a significant
increase in pregnancy and LBR rates following IVF. Couples in
this study (Reindollar 2010) were randomly assigned to (1) a con-
ventional pathway involving CC plus intrauterine insemination
(CC + IUI) followed by IUI + gonadotropins, then IVF, or (2)
an accelerated pathway (CC + IUI followed by six cycles of IVF).
Randomly assigned groups included similar numbers of women.
However, study populations in the other studies in this compari-
son (Goverde 2000; Goldman 2014; van Rumste 2014; Bensdorp
2015) differed from those of Reindollar 2010, as women in these
studies did not undergo CC + IUI treatment before receiving IUI
+ gonadotropins or IVF. Despite pretreatment with CC + IUI
in both randomly assigned arms, we believe the comparison be-
tween IUI + gonadotropins and IVF is valid. Thus our analysis
suggests that IVFmay be more effective than IUI + gonadotropins
in terms of pregnancy rate in treatment naive women and IVF
may be more effective than IUI+ gonadotropins in terms of preg-
nancy rate and LBR per woman among pretreated women, but
these results should be interpreted with caution. The single study
that compared CC + IUI with IVF in women 38 to 42 years of
age (Goldman 2014) also showed that pregnancy rates with IVF
were significantly higher than with CC + IUI.
Multiple pregnancy, an important adverse effect of superovula-
tion, was seen in four studies that compared IVF with IUI + go-
nadotropins (Goverde 2000; Goldman 2014; van Rumste 2014;
Bensdorp 2015). Results of the analysis suggest higher MPRs in
women who underwent IUI + gonadotropins compared with IVF,
but findings did not reach statistical significance. The maximum
number of embryos transferred was two among women younger
than 35 years, and three in women 35 years of age and older in
one study (Goverde 2000); up to two embryos were transferred in
the second study (van Rumste 2014). One good-quality embryo
was transferred in one study (van Rumste 2014), and two em-
bryos were transferred if no good-quality embryos were available.
Elective single embryo transfer (eSET) was followed in one study
(Bensdorp 2015). A further study used American Society for Re-
productive Medicine (ASRM) guidelines for day 3 embryo trans-
fers (Goldman 2014). Both twin pregnancies that occurred in the
IVF group in one included study occurred after transfer of two
non-top-quality embryos (van Rumste 2014). Protocols used for
ovarian stimulation also differed among the studies that tested this
comparison (Goverde 2000; Goldman 2014; van Rumste 2014).
A long protocol was followed that included a gonadotropin-releas-
ing hormone agonist and gonadotropins in two studies (Goverde
2000; van Rumste 2014). One study (Goldman 2014) used an
IVF protocol consisting of 21 days of an oral contraceptive fol-
lowed by a microdose gonadotropin-releasing hormone agonist,
followed by the addition of gonadotropins at a twice-daily dosage
for three days, beginning on day 3 or 4 of the agonist. Standard-
isation of the number of embryos transferred and the protocols
used for ovarian stimulation should be considered in trials related
to subfertility.
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Quality of the evidence
See Figure 1 and Figure 2.
Few high-quality randomised controlled trials (RCTs) have con-
ducted head-to-head comparisons of relevant interventions in the
context of unexplained subfertility. Most studies are methodolog-
ically inadequate. Only eight trials were eligible for inclusion in
the final analysis. Meta-analysis was possible in three comparisons.
One comparison was represented by a single trial only. This was
compounded by insufficient information on some outcomes. All
trials reported LBR per woman or couple, although duration of
follow-up in most trials was limited. The method of randomisa-
tion was unclear in some trials, and most had small sample sizes.
Blinding could not be performed in most studies because of the
nature of the interventions, but this was unlikely to affect out-
comes measured in the review. One trial was unpublished. An-
other study reporting only per-cycle data was excluded from the
review (Crosignani 1991).
Existing trials have several limitations. The definition of unex-
plained infertility and the clinical procedures and protocols used
vary among studies. It is unreasonable to expect absolute exper-
imental uniformity among study centres, and different centres
inevitably display variation in the application of assisted repro-
duction treatments (ARTs). Duration of follow-up is limited and
unequal between studies. Sample sizes of the studies included in
this review are also limited. Most trials show poor methodological
quality.Methods of randomisation and reasons for and numbers of
dropouts and withdrawals often are not clearly stated. Inadequate
methods of randomisation can lead to bias in estimates of treat-
ment effects (Schulz 1995). Allocation concealment is inadequate
in most trials. Intention-to-treat analysis is not always performed,
possibly leading to exaggerated estimates of treatment effect and
possible influence on inferences and clinical decisions. Most trials
have determined pregnancy rates per cycle as the endpoint, but
LBRper woman is themost important outcome to the couple. The
latest updated Cochrane guidelines for analysing and presenting
results emphasise the use of pregnancy and LBRs per woman or
couple in the final meta-analysis. However, in practice such data
are seldom available. Therefore, only a limited number of trials
could be included in this review. Most trials had limited duration
of follow-up. Information on costs associated with various fertility
treatments is also very limited. Reported cost-effectiveness analy-
ses are lacking in their definitions of outcome measures and extent
of cost analysis.
Clinical heterogeneity between trials is present as the result of
differences between studies in terms of investigation protocols and
inclusion criteria. The protocols used for ovarian stimulation also
differ. Timing of IUI and method of sperm preparation are not
clearly defined in some studies. The sample size of these studies is
limited. The following three analyses are included.
IVF versus expectant management for unexplained
subfertility
Evidence for live birth or pregnancy per randomly assignedwoman
was downgraded by three levels because of very serious impreci-
sion: The 95% confidence interval (CI) was too large, and rela-
tively few events were reported in the included studies. Moreover,
applicability was questionable (with respect to duration of unex-
plained infertility and co-interventions) (Summary of findings for
the main comparison).
IVF versus unstimulated IUI for unexplained
subfertility
Evidence for live birth or pregnancy per randomly assignedwoman
was downgraded by two levels because of serious imprecision: The
95% CI was relatively wide. Besides, only two studies included a
limited number of participants (n = 156) (Summary of findings
2).
IVF versus IUI + ovarian simulation with
gonadotropins or clomiphene for unexplained
subfertility
Evidence for outcomes in this comparison was downgraded from
one to two levels for various reasons (Summary of findings 3),
including imprecision, risk of bias in one trial and few events in
the included trials.
We identified three studies that determined the incidence of ovar-
ian hyperstimulation syndrome (OHSS) in women who under-
went IVF and IUI + gonadotropins (Goverde 2000; Goldman
2014; van Rumste 2014). However, as data were reported per cycle
in one of these trials (van Rumste 2014), only two trials were in-
cluded in the analysis for this outcome (Goverde 2000; Goldman
2014). Although no significant differences were noted in the in-
cidence of OHSS between these two treatment groups, the sam-
ple size was too small to allow firm conclusions. In the trial that
reported OHSS per cycle (van Rumste 2014), two of 48 couples
in the IVF group that reached embryo transfer were cancelled as
the result of OHSS, and of the 142 started cycles of IUI + go-
nadotropins, 14 cycles were cancelled because of the risk of mul-
tiple pregnancy (10%).
Potential biases in the review process
Definition of unexplained infertility
Wide inconsistency can be seen in the definition of unexplained
infertility. The definition used for this review follows here.
Couples with unexplained infertility were defined as:
• couples who have tried to conceive for 1 year;
• those with no abnormality identified during the full
infertility investigation, laboratory evidence of ovulation (normal
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luteal progesterone in serum), evidence of tubal patency and
exclusion of other tubal or pelvic abnormalities by
hysterosalpingography or laparoscopy, or both; and
• those producing a normal semen sample according to the
definition of normality provided by the World Health
Organization (WHO), in accordance with the year the study was
performed.
Only three trials reported secondary outcomes such as costs per
cycle and costs per couple. Economic evaluation of fertility treat-
ment is an important factor in decision making. Trials evaluating
the cost-effectiveness of available treatments for unexplained in-
fertility are very limited. To date, no studies have compared costs
of IVF treatment versus expectant management and CC in the
context of RCTs. Only four studies of cost-effectiveness in ART
were based on RCTs (Karande 1998; Goverde 2000; Reindollar
2010; van Rumste 2014). The study of Karande 1998 compared
an assumed equity in costs based on mathematical modelling be-
tween IVF as first-line treatment and a traditional treatment al-
gorithm and showed a much higher cost per pregnancy for IVF.
Goverde 2000, in a prospective, parallel-group study, reported that
costs of one IVF treatment cycle were 3.5 and 5 times higher than
those of one IUI treatment for stimulated and spontaneous cy-
cles, respectively. van Rumste 2014 reported an additional cost of
EUR 600 per couple with IVF with eSET compared with IUI +
superovulation. Reindollar 2010 also reported cost-effectiveness
of various treatments; however, specific costs for IVF and IUI +
superovulation could not be extracted from the data provided.
Agreements and disagreements with other
studies or reviews
No other systematic reviews on interventions for unexplained in-
fertility are currently available. Most interventions have been in-
troduced into clinical practice without adequate testing in the con-
text of large RCTs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
IVF may be associated with higher live birth rates than expectant
management, but there is insufficient evidence to draw firm con-
clusions. IVF may also be associated with higher live birth rates
than unstimulated IUI. In women pretreated with clomiphene +
IUI, IVF appears to be associated with higher birth rates than IUI
plus gonadotropins. However in women who are treatment-naive
there is no conclusive evidence of a difference in live birth rates
between IVF and IUI plus gonadotrophins or between IVF and
IUI plus clomiphene. Adverse events associated with these inter-
ventions could not be adequately assessed owing to lack of evi-
dence.
Clinicians and couples should balance the invasive nature of IVF
and related costs against chances of success with other treatment
modalities.
Implications for research
Some of the difficulties encountered in preparation of this review
can be avoided by planning infertility trials with similar study
designs and methods and presentation of results. This will allow
pooling of data for statistical meta-analysis.
Large RCTs with sufficient power are warranted. Unexplained
infertility should be clearly defined. Participant characteristics
should be clear (age, duration of infertility, parity, infertility in-
vestigations and previous therapy). These trials should have a pro-
longed duration of follow-up (e.g. six cycles of treatment). Treat-
ment protocols, methods of sperm preparation, numbers of em-
bryos transferred and inclusion and exclusion criteria should be
clearly stated.
Outcome measures should include LBRs per woman. As compar-
ison of cumulative LBRs is also important, trialists should endeav-
our to follow participants until frozen transfers accruing from a
single oocyte retrieval procedure are completed. In trials in which
controlled ovarian hyperstimulation is used, the number of mul-
tiple pregnancies and the incidence of OHSS should be stated.
Future trials should use adequate methods of randomisation, and
numbers of and reasons for dropouts and withdrawals should be
clearly stated. Allocation concealment should be adequate, and
intention-to-treat analysis performed. A power calculation should
be performedwith a clear description of the improvement in treat-
ment outcome that is considered clinically significant. Use of par-
allel-group rather than cross-over trials is favoured in the study of
events, as the latter may exaggerate the effectiveness of treatment.
IVF versus expectant management and IVF versus IUI + ovarian
stimulationwith gonadotropins or clomiphene or letrozole require
comparison in large RCTs with participants of varying prognos-
tic profiles. It is important to identify the group of patients with
certain prognostic profiles who would benefit by proceeding from
expectant management to more invasive treatment. The most ap-
propriate time to switch over from expectant management in this
group should be identified.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bensdorp 2015
Methods Multi-centre open-label 3-armparallel-group randomised controlled non-inferiority trial
Participants 602 couples seeking fertility treatment after ≥ 12 months of unprotected intercourse,
with the female partner between 18 and 38 years, an unfavourable prognosis for natural
conception and a diagnosis of unexplained or mild male subfertility. Exclusion criteria
included anovulation, double-sided tubal disease, severe endometriosis, premature ovar-
ian failure and known endocrine disorders (e.g. Cushing syndrome, adrenal hyperplasia)
Interventions Three cycles of IVF-SET (plus subsequent cryo-cycles), six cycles of modified natural
cycle IVF and six cycles of IUI-COH within 12 months after randomisation. Any addi-
tional treatments provided during this period were included at follow-up
Outcomes Main outcome measures: The primary outcome was birth of a healthy child resulting
from a singleton pregnancy conceived within 12 months after randomisation. Secondary
outcomes included live birth, clinical pregnancy, ongoing pregnancy,multiple pregnancy,
time to pregnancy, pregnancy complications and neonatal morbidity and mortality
Notes States: “During our trial the results of a pilot study, randomising women to three cycles
of IUI-COH or one cycle of IVF-SET, were published. This pilot study demonstrated
that the policy of transferring two embryos when no good quality embryos are available
is not effective in preventing multiple pregnancies. The study protocol was amended,
and from February 2010, after allocation of 48 women to the IVF-SET group, a strict
single embryo transfer policy (i.e. single embryo transfer was performed irrespective of
embryo quality) was implemented”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed with an
“online randomisation program, using bi-
ased coin minimisation, stratified for study
centre”
Allocation concealment (selection bias) Low risk “A web based program generated a unique
number with allocation code after entry
of the patient’s initials and date of birth.
Neither the recruiters nor the trial project
group could access the randomisation se-
quence”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not possible because of the
nature of the interventions
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Bensdorp 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 602/602 randomly assigned women were
included in the ITT analysis
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk None was suspected
Elzeiny 2014
Methods Randomised controlled parallel trial
Participants 44 couples
Inclusion criteria
Adults who had primary or secondary infertility ≥ 1 year in duration with evidence of
ovulation and tubal patency, aged 18 to 42 years for females and 18 to 60 years for males
Exclusion criteria
IUI or IVF treatment in the previous 12 months, coital disorder, untreated ovulatory
disorders or endometriosis (American Fertility Society criteria grades 2 to 4), tubal ob-
struction, abnormal semen analyses (concentration < 20 × 106/mL, progressive motility
< 25%, abnormal morphology > 95% or positive sperm antibodies) or any contraindi-
cation for multiple pregnancy
Interventions IVF vs IUI
Outcomes Live birth rate, clinical pregnancy rate, multiple pregnancy rate, OHSS, cost per live
birth
Notes Financial support provided by a pharmaceutical company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated, adaptive-biased coin ran-
domisation schedule”
Allocation concealment (selection bias) Low risk “sequentially numbered opaque sealed en-
velopes”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk 43/44 randomly assigned women were included
in the analysis
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Elzeiny 2014 (Continued)
Selective reporting (reporting bias) Low risk Study reported primary and secondary treat-
ment outcomes adequately including adverse
outcomes
Other bias Low risk No other potential bias could be observed
Goldman 2014
Methods Randomised controlled parallel trial, with clinicians blinded to outcome determinations.
Intention-to-treat analysis performed, numbers of and reasons for withdrawals and drop-
outs stated, clearly defined interventions applied with standardised protocols, couples
followed up until discharge from the hospital of both mother and infant(s), if pregnant,
or 1 year after completion of treatment protocol. Tables with permuted blocks of varying
sizes, stratified by the woman’s age (38th to 41st vs 42nd to 43rd birthday)
Participants 154 couples
Inclusion criteria
Couples in which the woman had 38 to 42 years 6 months of attempted conception; at
least 1 ovary and ipsilateral patent fallopian tube confirmed by hysterosalpingogram or
laparoscopy; regular menstrual cycles of 21 to 45 days; and no pelvic pathology, ectopic
pregnancy nor previous infertility treatment (except up to 3 cycles of clomiphenewithout
IUI). Normal prolactin and thyroid-stimulating hormone levels and body mass index
(BMI) < 38 in the woman; sperm concentration > 15 million total motile sperm or > 5
million total motile sperm at reflex IUI preparation in the male partner
Exclusion criteria
Age outside the range, prior infertility treatment or not a candidate for study treatments,
or not covered by a participating insurer
Interventions Three-arm randomised controlled trial. Couples were randomly assigned to treatment
with 2 cycles of clomiphene citrate (CC) and intrauterine insemination (IUI), follicle-
stimulating hormone (FSH)/IUI or immediate IVF, followed by by 3 cycles of IVF if
not pregnant
Outcomes Live birth, clinical pregnancy, multiple pregnancy and time to conception were reported
Notes Population of the study consisted of women with relatively advanced reproductive age
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation sequence was generated by
an independent biostatistician”, using ta-
bles with permuted blocks of varying sizes,
stratified by the woman’s age (38th to 41st
vs 42nd to 43rd birthday)
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Goldman 2014 (Continued)
Allocation concealment (selection bias) Low risk Remote allocation: “The allocation se-
quence was ... implemented by an epidemi-
ologist. Randomization was never con-
ducted by clinical staff ”
Blinding (performance bias and detection
bias)
All outcomes
Low risk All clinical investigators were blinded to
outcome determinations
Incomplete outcome data (attrition bias)
All outcomes
Low risk 154/154 randomly assigned women were
included in the ITT analysis
Selective reporting (reporting bias) Low risk Live birth, clinical pregnancy, multiple
pregnancy and time to conception were re-
ported
Other bias Low risk No other potential bias could be observed
Goverde 2000
Methods Randomised controlled parallel trial, participants and providers unable to be blinded,
intention-to-treat analysis performed, numbers of and reasons for withdrawals and drop-
outs stated, clearly defined interventions applied with standardised protocols, overall du-
ration of follow-up 6 cycles. Computer-generated randomisation schedule, administered
by numbered masked and sealed envelopes
Participants 181 women with unexplained or mild male factor infertility of at least 3 years’ duration
or male subfertility for ≥ 1 year, with no abnormality found during full infertility in-
vestigation, which included basal body temperature chart, late luteal phase endometrial
biopsy, postcoital test, hysterosalpingogram, diagnostic laparoscopy and≥ 2 semen anal-
yses. Exclusion criteria included cycle disorders, untreated endometriosis (AFS grade 2
to 4), and bilateral occluded tubes
Interventions IVF vs IUI and IVF vs intrauterine insemination plus ovarian stimulation (IUI + SO)
Outcomes LBR per woman/couple
Notes Power calculation mentioned
Number of dropouts before completion of treatment: IUI, 19 couples out of 86 randomly
assigned; IUI + SO, 16 out of 85 randomly assigned; IVF, 39 out of 87 randomly assigned
(figures include couples with unexplained subfertility and mild male factor subfertility)
Risk of bias
Bias Authors’ judgement Support for judgement
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Goverde 2000 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated
Allocation concealment (selection bias) Low risk “numbered masked and sealed envelopes”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk 172/181 (95%) randomly assigned women
with idiopathic subfertility were included
in the analysis
Selective reporting (reporting bias) Low risk Study reported primary and secondary
treatment outcomes adequately including
adverse outcomes
Other bias Low risk Pre-study power calculation was per-
formed, and no other potential bias was ob-
served
Hughes 2004
Methods 139 women in a multi-centre randomised controlled trial (RCT). Randomisation was
based on a blocked schedule using numbered, sealed, opaque envelopes and stratified by
centre; female age (≥ 35 years) and presence or absence of abnormal sperm (total sperm
count ≥ 20 million). Power calculation done. Intention-to-treat analysis performed.
Fisher’s exact test used for analysis. Confidence intervals calculated using Mantel-Haen-
szel statistics
Participants Duration of subfertility≥ 2 years (defined as no live birth during that time), no previous
IVF treatment, female age 18 to 39 years, day 3 serum follicle-stimulating hormone
(FSH) level ≥ 15 IU/L or standard level for inclusion in an individual centre’s IVF
programme, whichever level was lower; semen analysis within past 6 months showing
adequate sperm number to perform intracytoplasmic sperm injection (ICSI), evidence
of tubal patency by hysterosalpingography or laparoscopy
Mean duration of subfertility was 58 months. All couples had exhausted appropriate
lower intensity treatment options, such as ovulation induction and intrauterine insemi-
nation
Interventions First cycle of IVF compared with 90 days of no treatment (expectant management)
Outcomes Clinically viable pregnancy rate per couple, LBR per couple
Notes
Risk of bias
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Hughes 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk States: “Random allocation was based on a
blocked schedule using numbered, sealed,
opaque envelopes”
Allocation concealment (selection bias) Low risk “Random allocation was based on a
blocked schedule using numbered, sealed,
opaque envelopes”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk 68/68 randomly assigned women analysed
by intention-to-treat
Selective reporting (reporting bias) Low risk Study reported primary and secondary
treatment outcomes adequately including
adverse outcomes
Other bias High risk Pre-study power calculation was per-
formed,.and no other potential bias could
be observed
Reindollar 2010
Methods RCTusingpermuted blocks of varying sizes, stratified bywoman’s age (< 35 vs≥ 35 years)
, laparoscopywithin past year (yes or no) and study site (Boston IVF orHarvardVanguard
Medical Associates). Allocation sequence was produced by random numbers generated
by a congruence method. Investigators were blinded to all outcome determinations
Participants 503 couples; women 21 to 39 years of age with unexplained infertility and mild male
factor of 12 months’ duration
Interventions Couples in this study were randomly assigned to conventional pathway involving
clomiphene citrate plus intrauterine insemination (CC + IUI) followed by IUI + go-
nadotropins and then IVF; or accelerated pathway (CC + IUI followed by 6 cycles of
IVF)
Outcomes Pregnancy rate per cycle, pregnancy rate per couple, LBR per cycle, LBR per couple,
time to pregnancy, charge data
Notes Study could not be included for comparison between IVF and IUI + CC, as both arms
received CC + IUI
Risk of bias
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Reindollar 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation sequence was produced by
use of randomnumbers generated by a con-
gruence method. The sequence was devel-
oped by the biostatistician
and implemented by the epidemiologist”
Allocation concealment (selection bias) Low risk Apparently remote allocation: “The se-
quencewas ...implemented by the epidemi-
ologist”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators were blinded to all outcome
determinations; allocation was performed
by a biostatistician and was implemented
by an epidemiologist
Incomplete outcome data (attrition bias)
All outcomes
Low risk 503/503 randomly assigned women anal-
ysed by intention-to-treat
Selective reporting (reporting bias) Low risk Study authors published preliminary re-
sults in 2007 and did not appear to publish
or failed to publish based on results of the
trial
Other bias Low risk No other potential biases could be detected
Soliman 1993
Methods RCT; participant and provider could not be blinded. Follow-up was 1 cycle in the IVF
group and 6 months in the expectant management group
Participants 245 couples with infertility for 1 year, completed investigation for infertility, woman <
40 years. Mean duration of infertility 65 months, all previously treated by conventional
means
Only 35 couples had unexplained infertility and are included in analysis in this review
Interventions IVFvs expectantmanagement.Durationof expectantmanagementwas 6months, during
which time other treatments (apart from IVF) were permitted
Outcomes Pregnancy rate per woman/couple
Notes Computer-generated random number table. 16 cycles (16.2%) cancelled after start of
treatment for various reasons
For couples randomly assigned to expectant treatment, any form of infertility treatment
other than IVF was permitted for the 6-months expectant management arm. 78% of
couples received some form of infertility treatment except IVF while in the expectant
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Soliman 1993 (Continued)
arm
Despite randomisation, a significant difference was noted between mean ages of partic-
ipants in the 2 arms of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated
Allocation concealment (selection bias) Unclear risk This was not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No blinding was performed because of the
nature of the intervention used
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis was per-
formed. 19% of participants overall with-
drew (unclear how many with unexplained
infertility withdrew)
Selective reporting (reporting bias) Unclear risk Informationwas insufficient for judgement
of the trial as low risk or high risk
Other bias High risk Withdrawals were numerous; exact time of
withdrawal was not defined, especially for
the expectant management group. Groups
were not balanced with regard to prognos-
tic factors: IVF group were older and had
higher proportion with endometriosis
van Rumste 2014
Methods Multi-centre RCT
Participants 116 couples with unexplained and mild male factor infertility. All couples had a stan-
dard fertility workup, including assessment of ovulation by basal temperature curve or
ultrasound, a tubal patency test and sperm analysis. This study included all couples with
unexplained or mild male subfertility, female age between 18 and 38 years and poor
fertility prospects, defined as a 12-month prognosis < 30% for natural conception ac-
cording to the model of Hunault 2004
Interventions 1 cycle of IVF-eSET followed by 1 cryocycle or 3 cycles of IUI-ovarian stimulation.
Results of freeze-thaw cycles were also included in this study, provided the transfer took
place within 4 months after randomisation
Outcomes Ongoing pregnancy rate per woman/couple, cost per cycle
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van Rumste 2014 (Continued)
Notes Additional data on methods and outcomes were requested from lead author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central Internet-based randomisation was stratified by centre
Allocation concealment (selection bias) Unclear risk This was not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was performed
Selective reporting (reporting bias) Low risk No other reports on the trial could be retrieved
Other bias Low risk No other potential bias was noted
Abbreviations:
AFS: American Fertility Society.
eSET: elective single embryo transfer.
FSH: follicle-stimulating hormone.
ICSI: intracytoplasmic sperm injection.
IUI: intrauterine insemination.
IUI-COH: intrauterine insemination-controlled ovarian hyperstimulation.
IVF: in vitro fertilisation.
IVF-SET: in vitro fertilisation-single embryo transfer.
LBR: live birth rate.
SO: ovarian stimulation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Crosignani 1991 Multi-centre randomised controlled trial (RCT) comparing effectiveness of in vitro fertilisation (IVF) vs in-
trauterine insemination plus ovarian stimulation (IUI + gonadotropins) and IVF vs gamete intrafallopian transfer
(GIFT). Pregnancy rate per cycle and live birth rate (LBR) per cycle were reported outcomes
Custers 2012 Couples with unexplained subfertility and intermediate prognosis of natural conception were randomly allocated
to 6 months EM or immediate start with IUI-COS: no IVF arm
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(Continued)
Jarrell 1993 Diagnostic stratification not done; therefore number of participants with unexplained infertility is not known.
Control group could include participants who underwent some form of fertility treatment while awaiting spon-
taneous pregnancy
Karande 1998 Diagnostic stratification not done. Study population included all categories of infertile couples. Couples with
unexplained infertility were not analysed separately
Leeton 1987 Although study authors describe the study as randomised controlled trial (RCT), on closer inspection the method
of allocation was found to be non-random. Every second participant was allocated to the gamete intrafallopian
transfer (GIFT) group
Raneiri 1995 No intervention of interest (gamete intrafallopian transfer (GIFT) excluded from 2011 review update)
Tanbo 1990 No intervention of interest (gamete intrafallopian transfer (GIFT) excluded from 2011 review update)
Zayed 1997 Randomisation was not genuine. Study authors describe method of randomisation as pseudo-randomisation.
Allocation of treatment was breached by participant preference. Pregnancy and live birth rate (LBR) per woman/
couple has not been reported
Characteristics of ongoing studies [ordered by study ID]
Nandi 2015
Trial name or title Controlled ovarian stimulation and intrauterine insemination or in vitro fertilisation as first-line treatment
for unexplained infertility: a randomised controlled trial
Methods Randomised controlled trial (RCT)
Participants Inclusion criteria
• Age of female partner between 23 and 37 years
• Diagnosis of unexplained infertility at time of first treatment
• Inability to conceive following minimum of 1 year of unprotected intercourse
• In the presence of normal semen analysis, proof of regular ovulatory cycles with day 3 follicle-
stimulating hormone (FSH) < 10 IU/L
• 2 patent tubes and normal uterine cavity on hysterosalpingography (HSG)
Exclusion criteria
• Female partner ≥ 37 years of age
• Physical disability or psychosexual problems with difficulty achieving vaginal intercourse
• Same sex relationship (as these do not fall under the definition of unexplained infertility)
• Male/female is human immunodeficiency virus (HIV) positive, as these couples would need specific
consideration regarding methods of conception
• No previous intrauterine insemination (IUI) or in vitro fertilisation (IVF) treatment for infertility
Interventions Randomisation is performed by an independent worker in blocks of 10 and distributed in individual consec-
utively numbered opaque envelopes. Participants will be randomly assigned to 2 groups:
• Group 1: controlled ovarian hyperstimulation (COH) + IUI. In COH + IUI group, controlled ovarian
hyperstimulation can be performed with daily subcutaneous injections of 75 IU FSH, from day 3 to 4 of
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Nandi 2015 (Continued)
menstrual cycle onwards. If ≥ 3 follicles > 16 mm develop, the cycle would be cancelled. Single
insemination will be done
• Group 2: IVF
In IVF group, women will undergo controlled ovarian hyperstimulation after downregulation with go-
nadotropin releasing hormone (GnRH) agonist in a long protocol starting on day 2. COH is started with
FSH, with doses ranging from 150 to 450 IU, depending on initial anti-Mullerian hormone (AMH) level as
decided by attending clinician. Day of embryo transfer will be decided by embryologist base
Outcomes Primary outcome: singleton live birth
Secondary outcomes: clinical pregnancy rate, multiple pregnancy rate
Starting date 17/6/2013
Contact information Anupa Nandi
Homerton Fertility Unit Homerton Hospital
E9 6SR
London
United Kingdom
Notes http://isrctn.com/ISRCTN43430382
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D A T A A N D A N A L Y S E S
Comparison 1. IVF versus expectant management
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate per woman 1 51 Odds Ratio (M-H, Fixed, 95% CI) 22.0 [2.56, 189.37]
2 Clinical pregnancy rate per
woman
2 86 Odds Ratio (M-H, Fixed, 95% CI) 3.24 [1.07, 9.80]
Comparison 2. IVF versus unstimulated IUI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate per woman 2 156 Odds Ratio (M-H, Fixed, 95% CI) 2.47 [1.19, 5.12]
2 Clinical pregnancy rate per
woman
1 43 Odds Ratio (M-H, Fixed, 95% CI) 4.83 [0.94, 24.95]
3 Multiple pregnancy rate per
woman
1 43 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.04, 27.29]
Comparison 3. IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate per woman 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Treatment-naive women
IVF vs IUI + gonadotropins
4 745 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.94, 1.73]
1.2 Pretreated women IVF vs
IUI + gonadotropins
1 280 Odds Ratio (M-H, Fixed, 95% CI) 3.90 [2.32, 6.57]
1.3 Treatment-naive women
IVF vs IUI + CC
1 103 Odds Ratio (M-H, Fixed, 95% CI) 2.51 [0.96, 6.55]
2 Clinical pregnancy rate per
woman
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Treatment-naive women
IVF vs IUI + gonadotropins
3 627 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [1.03, 2.03]
2.2 Treatment-naive women
IVF vs IUI + CC
1 103 Odds Ratio (M-H, Fixed, 95% CI) 4.59 [1.86, 11.35]
2.3 Pretreated women IVF vs
IUI + gonadotropins
1 280 Odds Ratio (M-H, Fixed, 95% CI) 14.13 [7.57, 26.38]
3 Multiple pregnancy rate per
woman
4 848 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.47, 1.39]
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3.1 Treatment-naive women
IUI + gonadotropins
4 745 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.45, 1.39]
3.2 Treatment-naive women
IVF vs IUI + CC
1 103 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.20, 5.31]
4 Incidence of OHSS per woman 2 324 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.43, 3.06]
4.1 Treatment-naive women
IVF vs IUI + gonadotropins
2 221 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.36, 4.14]
4.2 Treatment-naive women
IVF vs IUI + CC
1 103 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.20, 5.31]
5 Miscarriage rate per woman 1 206 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.59, 2.28]
5.1 Treatment-naive women
IVF vs IUI + CC
1 103 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.44, 3.02]
5.2 Treatment-naive women
IVF vs IUI+ gonadotropins
1 103 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.44, 3.02]
Analysis 1.1. Comparison 1 IVF versus expectant management, Outcome 1 Live birth rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 1 IVF versus expectant management
Outcome: 1 Live birth rate per woman
Study or subgroup IVF Expectant Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hughes 2004 (1) 11/24 1/27 100.0 % 22.00 [ 2.56, 189.37 ]
Total (95% CI) 24 27 100.0 % 22.00 [ 2.56, 189.37 ]
Total events: 11 (IVF), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Expectant Favours IVF
(1) All women in this study were pretreated, with a mean of 4-5 years of infertility. Women had a wide range of diagnoses, 37% with explained infertility
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Analysis 1.2. Comparison 1 IVF versus expectant management, Outcome 2 Clinical pregnancy rate per
woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 1 IVF versus expectant management
Outcome: 2 Clinical pregnancy rate per woman
Study or subgroup IVF
Expectant
Manage-
ment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hughes 2004 12/24 3/27 38.2 % 8.00 [ 1.89, 33.85 ]
Soliman 1993 1/21 2/14 61.8 % 0.30 [ 0.02, 3.67 ]
Total (95% CI) 45 41 100.0 % 3.24 [ 1.07, 9.80 ]
Total events: 13 (IVF), 5 (Expectant Management)
Heterogeneity: Chi2 = 4.97, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Expectant Favours IVF
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Analysis 2.1. Comparison 2 IVF versus unstimulated IUI, Outcome 1 Live birth rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 2 IVF versus unstimulated IUI
Outcome: 1 Live birth rate per woman
Study or subgroup IVF Unstimulated IUI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elzeiny 2014 (1) 4/10 2/33 6.0 % 10.33 [ 1.53, 69.73 ]
Goverde 2000 (2) 24/59 14/54 94.0 % 1.96 [ 0.88, 4.36 ]
Total (95% CI) 69 87 100.0 % 2.47 [ 1.19, 5.12 ]
Total events: 28 (IVF), 16 (Unstimulated IUI)
Heterogeneity: Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 2.42 (P = 0.015)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours IUI Favours IVF
(1) Participants in IVF and IUI groups each had one treatment cycle
(2) This trial tested the effectiveness of IVF (6 cycles) versus IUI alone (6 cycles)
Analysis 2.2. Comparison 2 IVF versus unstimulated IUI, Outcome 2 Clinical pregnancy rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 2 IVF versus unstimulated IUI
Outcome: 2 Clinical pregnancy rate per woman
Study or subgroup IVF Unstimulated IUI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elzeiny 2014 (1) 4/10 4/33 100.0 % 4.83 [ 0.94, 24.95 ]
Total (95% CI) 10 33 100.0 % 4.83 [ 0.94, 24.95 ]
Total events: 4 (IVF), 4 (Unstimulated IUI)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IVF Favours Unstimulated IUI
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(1) Participants in IVF group underwent one IVF cycle while participants in IUI group underwent one IUI cycle
Analysis 2.3. Comparison 2 IVF versus unstimulated IUI, Outcome 3 Multiple pregnancy rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 2 IVF versus unstimulated IUI
Outcome: 3 Multiple pregnancy rate per woman
Study or subgroup IVF Unstimulated IUI Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elzeiny 2014 (1) 0/10 1/33 100.0 % 1.03 [ 0.04, 27.29 ]
Total (95% CI) 10 33 100.0 % 1.03 [ 0.04, 27.29 ]
Total events: 0 (IVF), 1 (Unstimulated IUI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IVF Favours Unstimulated IUI
(1) Participants in IVF group underwent one IVF cycle while participants in IUI group underwent one IUI cycle
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Analysis 3.1. Comparison 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC),
Outcome 1 Live birth rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome: 1 Live birth rate per woman
Study or subgroup IVF
IUI
+Ovarian
Stimulation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Treatment-naive women IVF vs IUI + gonadotropins
Bensdorp 2015 (1) 118/201 116/207 64.9 % 1.12 [ 0.75, 1.65 ]
Goldman 2014 16/51 7/52 6.5 % 2.94 [ 1.09, 7.92 ]
Goverde 2000 (2) 24/59 22/59 17.9 % 1.15 [ 0.55, 2.42 ]
van Rumste 2014 13/58 10/58 10.7 % 1.39 [ 0.55, 3.48 ]
Subtotal (95% CI) 369 376 100.0 % 1.27 [ 0.94, 1.73 ]
Total events: 171 (IVF), 155 (IUI +Ovarian Stimulation)
Heterogeneity: Chi2 = 3.27, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Pretreated women IVF vs IUI + gonadotropins
Reindollar 2010 (3) 58/111 37/169 100.0 % 3.90 [ 2.32, 6.57 ]
Subtotal (95% CI) 111 169 100.0 % 3.90 [ 2.32, 6.57 ]
Total events: 58 (IVF), 37 (IUI +Ovarian Stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 5.12 (P < 0.00001)
3 Treatment-naive women IVF vs IUI + CC
Goldman 2014 (4) 16/51 8/52 100.0 % 2.51 [ 0.96, 6.55 ]
Subtotal (95% CI) 51 52 100.0 % 2.51 [ 0.96, 6.55 ]
Total events: 16 (IVF), 8 (IUI +Ovarian Stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 13.86, df = 2 (P = 0.00), I2 =86%
0.1 0.2 0.5 1 2 5 10
Favours IUI + SO Favours IVF
(1) Women were randomised to receive 3 cycles of IVF or 6 cycles of IUI+SO
(2) Patients underwent a maximum of six treatment cycles of either IUI +SO or IVF.
(3) Couples were randomized to receive either three cycles of FSH/IUI or up to six cycles of IVF
(4) Couples were randomised to receive CC+IUI for two cycles or IVF for two cycles
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Analysis 3.2. Comparison 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC),
Outcome 2 Clinical pregnancy rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome: 2 Clinical pregnancy rate per woman
Study or subgroup IVF
IUI +
Ovarian
stimulation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Treatment-naive women IVF vs IUI + gonadotropins
Bensdorp 2015 (1) 135/201 132/207 75.8 % 1.16 [ 0.77, 1.75 ]
Goldman 2014 25/51 9/52 8.1 % 4.59 [ 1.86, 11.35 ]
van Rumste 2014 (2) 14/58 12/58 16.2 % 1.22 [ 0.51, 2.93 ]
Subtotal (95% CI) 310 317 100.0 % 1.45 [ 1.03, 2.03 ]
Total events: 174 (IVF), 153 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 7.52, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 2.15 (P = 0.031)
2 Treatment-naive women IVF vs IUI + CC
Goldman 2014 (3) 25/51 9/52 100.0 % 4.59 [ 1.86, 11.35 ]
Subtotal (95% CI) 51 52 100.0 % 4.59 [ 1.86, 11.35 ]
Total events: 25 (IVF), 9 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00095)
3 Pretreated women IVF vs IUI + gonadotropins
Reindollar 2010 (4) 95/111 50/169 100.0 % 14.13 [ 7.57, 26.38 ]
Subtotal (95% CI) 111 169 100.0 % 14.13 [ 7.57, 26.38 ]
Total events: 95 (IVF), 50 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 8.32 (P < 0.00001)
Test for subgroup differences: Chi2 = 41.36, df = 2 (P = 0.00), I2 =95%
0.05 0.2 1 5 20
Favours IUI+SO Favours IVF
(1) Women were randomised to receive 3 cycles of IVF or 6 cycles of IUI+SO
(2) One cycle of IVF versus three cycles of IUI+SO
(3) Couples were randomised to receive CC+IUI for two cycles or IVF for two cycles
(4) Couples were randomized to receive either three cycles of FSH/IUI or up to six cycles of IVF
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Analysis 3.3. Comparison 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC),
Outcome 3 Multiple pregnancy rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome: 3 Multiple pregnancy rate per woman
Study or subgroup IVF
IUI +
Ovarian
stimulation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Treatment-naive women IUI + gonadotropins
Bensdorp 2015 (1) 7/201 8/207 25.7 % 0.90 [ 0.32, 2.52 ]
Goldman 2014 4/51 3/52 9.3 % 1.39 [ 0.30, 6.55 ]
Goverde 2000 (2) 12/59 17/59 45.8 % 0.63 [ 0.27, 1.47 ]
van Rumste 2014 (3) 2/58 3/58 9.8 % 0.65 [ 0.11, 4.07 ]
Subtotal (95% CI) 369 376 90.5 % 0.79 [ 0.45, 1.39 ]
Total events: 25 (IVF), 31 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 0.88, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Treatment-naive women IVF vs IUI + CC
Goldman 2014 (4) 3/51 3/52 9.5 % 1.02 [ 0.20, 5.31 ]
Subtotal (95% CI) 51 52 9.5 % 1.02 [ 0.20, 5.31 ]
Total events: 3 (IVF), 3 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 420 428 100.0 % 0.81 [ 0.47, 1.39 ]
Total events: 28 (IVF), 34 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 0.97, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours IVF Favours IUI + OS
(1) Women were randomised to receive 3 cycles of IVF or 6 cycles of IUI+SO
(2) Patients underwent a maximum of six treatment cycles of either IUI +SO or IVF.
(3) One cycle of IVF versus three cycles of IUI+SO
(4) Couples were randomised to receive CC+IUI for two cycles or IVF for two cycles
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Analysis 3.4. Comparison 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC),
Outcome 4 Incidence of OHSS per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome: 4 Incidence of OHSS per woman
Study or subgroup IVF
IUI +
Ovarian
stimulation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Treatment-naive women IVF vs IUI + gonadotropins
Goldman 2014 3/51 3/52 37.3 % 1.02 [ 0.20, 5.31 ]
Goverde 2000 (1) 3/59 2/59 25.3 % 1.53 [ 0.25, 9.49 ]
Subtotal (95% CI) 110 111 62.7 % 1.23 [ 0.36, 4.14 ]
Total events: 6 (IVF), 5 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Treatment-naive women IVF vs IUI + CC
Goldman 2014 (2) 3/51 3/52 37.3 % 1.02 [ 0.20, 5.31 ]
Subtotal (95% CI) 51 52 37.3 % 1.02 [ 0.20, 5.31 ]
Total events: 3 (IVF), 3 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 161 163 100.0 % 1.15 [ 0.43, 3.06 ]
Total events: 9 (IVF), 8 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 0.13, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
0.01 0.1 1 10 100
Favours IVF Favours IUI + OS
(1) Patients underwent a maximum of six treatment cycles of either IUI +SO or IVF.
(2) Couples were randomised to receive CC+IUI for two cycles or IVF for two cycles
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Analysis 3.5. Comparison 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC),
Outcome 5 Miscarriage rate per woman.
Review: In vitro fertilisation for unexplained subfertility
Comparison: 3 IVF versus IUI + ovarian stimulation with gonadotropins or clomiphene (CC)
Outcome: 5 Miscarriage rate per woman
Study or subgroup IVF
IUI +
Ovarian
stimulation Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Treatment-naive women IVF vs IUI + CC
Goldman 2014 (1) 11/51 10/52 50.0 % 1.16 [ 0.44, 3.02 ]
Subtotal (95% CI) 51 52 50.0 % 1.16 [ 0.44, 3.02 ]
Total events: 11 (IVF), 10 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
2 Treatment-naive women IVF vs IUI+ gonadotropins
Goldman 2014 11/51 10/52 50.0 % 1.16 [ 0.44, 3.02 ]
Subtotal (95% CI) 51 52 50.0 % 1.16 [ 0.44, 3.02 ]
Total events: 11 (IVF), 10 (IUI + Ovarian stimulation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 102 104 100.0 % 1.16 [ 0.59, 2.28 ]
Total events: 22 (IVF), 20 (IUI + Ovarian stimulation)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours [IVF] Favours [IUI+Superovulat]
(1) Couples were randomised to receive CC+IUI for two cycles or IVF for two cycles
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A P P E N D I C E S
Appendix 1. MDSG search string
MDSG search string for ZP672 04/05/2015
Keywords CONTAINS “*Embryo Transfer” or “IVF” or “in vitro fertilisation” or “in-vitro fertilisation procedure” or “in-vitro fertilisa-
tion techniques” or “in vitro fertilization” or “ICSI” or “intracytoplasmic morphologically selected sperm injection” or “intracytoplasmic
sperm injection” or “intracytoplasmic sperm injection techniques” or “intracytoplasmic sperm injection cycle” or “zygote intrafallopian
transfer” or “zygote intrafallopian tube transfer” or “zygote transfer” or “ET” or “ZIFT” or Title CONTAINS “*Embryo Transfer”
or “IVF” or “in vitro fertilisation” or “in-vitro fertilisation procedure” or “in-vitro fertilisation techniques” or “in vitro fertilization”
or “ICSI” or “intracytoplasmic morphologically selected sperm injection” or “intracytoplasmic sperm injection” or “intracytoplasmic
sperm injection techniques” or “intracytoplasmic sperm injection cycle” or “zygote intrafallopian transfer” or “zygote intrafallopian
tube transfer” or “zygote transfer” or “ET” or “ZIFT”
AND
Keywords CONTAINS “expectant management” or “conservative treatment” or “*Clomiphene” or “clomiphene citrate” or “insem-
ination” or “insemination-fallopian tube sperm perfusion” or “insemination-utero tubal” or “insemination, intrauterine” or “insemi-
nation, intratubal” or “artificial insemination” or “IUI” or “Intrauterine Insemination” or “intrautero tuboperitoneal insemination” or
“gamete intrafallopian transfer” or “gamete intrauterine transfer” or “GIFT” or “waiting group” or “conventional insemination” or
“conventional” or Title CONTAINS “expectant management” or “conservative treatment” or “*Clomiphene” or “clomiphene citrate”
or “insemination” or “insemination-fallopian tube sperm perfusion” or “insemination-utero tubal” or “insemination, intrauterine ” or
“insemination, intratubal” or “artificial insemination” or “IUI” or “Intrauterine Insemination” or “intrautero tuboperitoneal insemina-
tion” or “gamete intrafallopian transfer” or “gamete intrauterine transfer” or “GIFT” or “waiting group” or “conventional insemination”
or “conventional”
AND
Keywords CONTAINS “unexplained and endometriosis related infertility” or “unexplained infertility” or “unexplained subfertility”
or “idiopathic subfertility” or “idiopathic-unexplained” or Title CONTAINS “unexplained and endometriosis related infertility” or
“unexplained infertility” or “unexplained subfertility” or “idiopathic subfertility” or “idiopathic-unexplained”
Appendix 2. MEDLINE search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or exp zygote intrafallopian transfer/
(33616)
2 (in Vitro adj2 fertili$).tw. (19493)
3 (ivf or icsi or ZIFT).tw. (20232)
4 (intracytoplas$ adj2 sperm).tw. (5395)
5 zygote intrafallopian transfer$.tw. (85)
6 (embryo transfer$ or ET).tw. (183294)
7 invitro fertili$.tw. (21)
8 or/1-7 (217509)
9 (expect$ adj2 manage$).tw. (2882)
10 (conservative treat$ or conservative therap$).tw. (29266)
11 exp Clomiphene/ (4871)
12 clomi$.tw. (7512)
13 exp insemination, artificial/ or exp insemination, artificial, homologous/ (10127)
14 (intrauter$ adj5 inseminat$).tw. (1987)
15 (intra-uter$ adj5 inseminat$).tw. (203)
16 (artificial adj2 inseminat$).tw. (5323)
17 IUI.tw. (1284)
18 (wait adj1 see).tw. (4)
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19 (conventional$ adj2 treat$).tw. (18913)
20 (conventional$ adj2 therap$).tw. (16421)
21 or/9-20 (86888)
22 8 and 21 (4387)
23 randomized controlled trial.pt. (392802)
24 controlled clinical trial.pt. (89296)
25 randomized.ab. (318096)
26 placebo.tw. (165979)
27 clinical trials as topic.sh. (172395)
28 randomly.ab. (229531)
29 trial.ti. (137219)
30 (crossover or cross-over or cross over).tw. (63820)
31 or/23-30 (976870)
32 exp animals/ not humans.sh. (4028709)
33 31 not 32 (899597)
34 22 and 33 (412)
Appendix 3. EMBASE search strategy
Database: Embase <1980 to 2015 Week 18>
Search Strategy:
--------------------------------------------------------------------------------
1 exp fertilization in vitro/ (40286)
2 exp intracytoplasmic sperm injection/ (13555)
3 exp embryo transfer/ (21998)
4 (in?Vitro adj2 fertili$).tw. (131)
5 (ivf or icsi or ZIFT).tw. (31068)
6 (intracytoplas$ adj2 sperm).tw. (6942)
7 zygote intrafallopian transfer$.tw. (94)
8 embryo transfer$.tw. (12285)
9 invitro fertili$.tw. (126)
10 or/1-9 (62146)
11 exp conservative treatment/ (406649)
12 (expect$ adj2 manage$).tw. (3988)
13 (conservative treatment or conservative therap$).tw. (35481)
14 exp clomifene/ (5121)
15 clomi$.tw. (9200)
16 exp artificial insemination/ (12692)
17 (intrauter$ adj5 inseminat$).tw. (2722)
18 (intra-uter$ adj5 inseminat$).tw. (326)
19 (artificial adj2 inseminat$).tw. (5059)
20 IUI.tw. (2103)
21 (wait adj1 see).tw. (11)
22 (conventional$ adj2 treat$).tw. (25546)
23 (conventional$ adj2 therap$).tw. (22310)
24 or/11-23 (501244)
25 Clinical Trial/ (843553)
26 Randomized Controlled Trial/ (369125)
27 exp randomization/ (66088)
28 Single Blind Procedure/ (20079)
29 Double Blind Procedure/ (119899)
30 Crossover Procedure/ (42594)
54In vitro fertilisation for unexplained subfertility (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
31 Placebo/ (255278)
32 Randomi?ed controlled trial$.tw. (114897)
33 Rct.tw. (16728)
34 random allocation.tw. (1402)
35 randomly allocated.tw. (22147)
36 allocated randomly.tw. (2011)
37 (allocated adj2 random).tw. (721)
38 Single blind$.tw. (15643)
39 Double blind$.tw. (149839)
40 ((treble or triple) adj blind$).tw. (440)
41 placebo$.tw. (212811)
42 prospective study/ (287679)
43 or/25-42 (1452441)
44 case study/ (31373)
45 case report.tw. (279675)
46 abstract report/ or letter/ (921238)
47 or/44-46 (1226085)
48 43 not 47 (1413427)
49 10 and 24 and 48 (908)
Appendix 4. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
Database: EBM Reviews - Cochrane Central Register of Controlled Trials <May 2015>
Search Strategy:
--------------------------------------------------------------------------------
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or exp zygote intrafallopian transfer/
(1755)
2 (in Vitro adj2 fertili$).tw. (1600)
3 (ivf or icsi or ZIFT).tw. (2762)
4 (intracytoplas$ adj2 sperm).tw. (531)
5 zygote intrafallopian transfer$.tw. (9)
6 (embryo transfer$ or ET).tw. (11550)
7 invitro fertili$.tw. (3)
8 or/1-7 (14071)
9 (expect$ adj2 manage$).tw. (407)
10 (conservative treat$ or conservative therap$).tw. (1609)
11 exp Clomiphene/ (387)
12 clomi$.tw. (1581)
13 exp insemination, artificial/ or exp insemination, artificial, homologous/ (294)
14 (intrauter$ adj5 inseminat$).tw. (499)
15 (intra-uter$ adj5 inseminat$).tw. (43)
16 (artificial adj2 inseminat$).tw. (99)
17 IUI.tw. (380)
18 (wait adj1 see).tw. (88)
19 (conventional$ adj2 treat$).tw. (4206)
20 (conventional$ adj2 therap$).tw. (3089)
21 or/9-20 (10790)
22 8 and 21 (502)
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Appendix 5. PsycINFO search strategy
Database: PsycINFO <1806 to April Week 4 2015>
Search Strategy:
--------------------------------------------------------------------------------
1 (in?Vitro adj2 fertili$).tw. (3)
2 (ivf or icsi or ZIFT).tw. (435)
3 (intracytoplas$ adj2 sperm).tw. (43)
4 zygote intrafallopian transfer$.tw. (2)
5 embryo transfer$.tw. (101)
6 invitro fertili$.tw. (3)
7 (expect$ adj2 manage$).tw. (506)
8 (conservative treat$ or conservative therap$).tw. (301)
9 clomi$.tw. (1789)
10 (intrauter$ adj5 inseminat$).tw. (21)
11 (intra-uter$ adj5 inseminat$).tw. (0)
12 (artificial adj2 inseminat$).tw. (235)
13 IUI.tw. (24)
14 (wait adj1 see).tw. (1)
15 (conventional$ adj2 treat$).tw. (1331)
16 (conventional$ adj2 therap$).tw. (754)
17 or/1-6 (515)
18 or/7-16 (4831)
19 17 and 18 (30)
20 random.tw. (43430)
21 control.tw. (337122)
22 double-blind.tw. (18791)
23 clinical trials/ (8613)
24 placebo/ (4057)
25 exp Treatment/ (613111)
26 or/20-25 (940087)
27 19 and 26 (8)
Appendix 6. CINAHL search strategy
CINAHL search strategy for ZP672 on 04/05/2015
# Query Results
S35 S22 AND S34 86
S34 S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR S31 OR S32 OR S33
957,665
S33 TX allocat* random* 4,263
S32 (MH “Quantitative Studies”) 13,366
S31 (MH “Placebos”) 9,206
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(Continued)
S30 TX placebo* 33,746
S29 TX random* allocat* 4,263
S28 (MH “Random Assignment”) 39,076
S27 TX randomi* control* trial* 86,804
S26 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
765,707
S25 TX clinic* n1 trial* 171,460
S24 PT Clinical trial 77,813
S23 (MH “Clinical Trials+”) 186,869
S22 S7 AND S21 253
S21 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR
S15 OR S16 OR S17 OR S18 OR S19 OR S20
10,884
S20 TX(conventional* N2 therap*) 2,360
S19 TX (conventional* N2 treat*) 2,754
S18 TX (wait N1 see) 216
S17 TX IUI 79
S16 TX(artificial* N2 inseminat*) 455
S15 TX(intra-uter* N3 inseminat*) 9
S14 TX(intrauter* N3 inseminat*) 154
S13 (MM “Insemination, Artificial”) 243
S12 TX clomi* 536
S11 (MM “Clomiphene”) 109
S10 TX(conservative Therap*) 904
S9 TX(conservative treat*) 3,472
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(Continued)
S8 TX(expect* N2 manage*) 922
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6 3,499
S6 TX (intracytoplas* N2 sperm) 241
S5 TX embryo* N3 transfer* 777
S4 TX IVF or TX ICSI 1,252
S3 (MM “Fertilization in Vitro”) 1,450
S2 TX vitro fertilization 2,863
S1 TX vitro fertilisation 267
Appendix 7. Trial characteristics
(1) Method of randomisation:
(a) third party randomisation: for example computer, telephone randomisation
(b) true randomisation by trialist: for example sequentially numbered, sealed, opaque envelopes, register, on-site computer system
(c) quasi randomised: for example by alternation, record-numbers, date of birth, open list of random numbers, open envelopes
(d) method not stated
(2) Study design:
(a) presence or absence of blinding to randomisation
(b) cross-over or parallel design
(c) duration of follow-up
(d) type of follow-up
(3) Size of the studies:
(a) numbers of women recruited
(b) numbers of women randomised
(c) numbers of women excluded
(d) numbers of women analysed
(e) numbers of women lost to follow-up
(f ) details of dropouts given
(4) Study setting:
(a) single or multicentre
(b) location
(c) timing
(5) Analysis:
(a) sample size with power calculation
(b) whether or not analysed by “intention to treat”:
(i) done
(ii) not done, but possible
(iii) not possible
(iv) uncertain
(c) subgroup analysis for couples with subfertility due to minimal endometriosis
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Characteristics of the study participants:
(1) Couples with unexplained infertility in whom full infertility investigations yielded normal results:
• normal luteal phase progesterone
• tubal patency assessed by hysterosalpingography and/or laparoscopy
• normal semen sample according to World Health Organization (WHO) guidelines for the year the study was performed
(2) Baseline characteristics:
(a) age of the female partner
(b) primary or secondary infertility
(c) duration of subfertility
(d) previous fertility treatment
(3) Other subgroup criteria:
(a) Couples with minimal endometriosis (American Fertility Society criteria grade I), with subfertility
Baseline characteristics mentioned in (2) above were considered
(4) Interventions used:
(a) expectant management
(b) clomiphene citrate
(c) intrauterine insemination alone
(d) intrauterine insemination with controlled ovarian stimulation
(e) in vitro fertilisation
(f ) gamete intrafallopian transfer
(5) Outcomes:
Primary:
(a) cumulative live birth rate per woman/couple
Secondary:
(a) pregnancy rate
(i) per woman/couple
(ii) cumulative
(iii) per treatment cycle commenced
(b) live birth rate
(i) cumulative
(ii) per cycle commenced
(c) multiple pregnancy rate
(i) per woman
(d) ovarian hyperstimulation syndrome (OHSS)
(i) per woman
(e) costs
(i) per treatment cycle
(ii) per couple
WH A T ’ S N E W
Last assessed as up-to-date: 4 May 2015.
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Date Event Description
5 May 2015 New search has been performed Three new studies have been added (Elzeiny 2014;
Goldman 2014; Bensdorp 2015). A follow up of a study
previously included as two separate studies (Custers et
al 2011; van Rumste 2009) has been published and is
included in this review (van Rumste 2014). IVF versus
clomiphene has been removed from the comparisons. IVF
versus IUI + clomiphene has been added to the compar-
isons
5 May 2015 New citation required but conclusions have not changed The conclusions of this review have not changed with the
addition of new evidence
H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 2, 2002
Date Event Description
23 February 2011 New citation required but conclusions have not
changed
Three studies have been excluded: two (Tanbo 1990;
Raneiri 1995) because gamete intrafallopian transfer
(GIFT) has been removed from the comparisons, as
this treatment is rarely used now, and one (Crosignani
1991) as only per-cycle data were reported. Per-cycle
data from all comparisons have been deleted.One new
study has been added to the comparison IVF versus
unstimulated IUI (Elzeiny 2014). Two new studies
have been added (Goldman 2014; Bensdorp 2015) to
the comparison of in vitro fertilisation (IVF) versus in-
trauterine insemination plus ovarian stimulation (IUI
+ SO). One new study has been added to the compar-
ison IVF versus IUI + clomiphene (Goldman 2014)
1 September 2010 New citation required and conclusions have changed Substantive amendments have been made
12 November 2008 Amended This review has been converted to the new review for-
mat
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• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Gamete intrafallopian transfer (GIFT) has been removed from the comparisons and the review. The primary outcome of cumulative
live birth rate per woman has been replaced by live birth rate per woman, and the secondary outcome of cumulative pregnancy rate
per woman has been replaced by clinical pregnancy rate per woman. The comparison of in vitro fertilisation (IVF) versus intrauterine
insemination (IUI) + letrozole has been added.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Live Birth; Clomiphene [therapeutic use]; Fertility Agents, Female [therapeutic use]; Fertilization in Vitro [∗methods]; Gamete
IntrafallopianTransfer; Infertility, Female [∗therapy]; Insemination, Artificial [methods];Ovulation Induction; RandomizedControlled
Trials as Topic
MeSH check words
Female; Humans
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